Document:

License Agreement, dated as of January 10, 2000 - as amended on July 28, 2003

 Exhibit 10.17 
 Confidential Materials omitted and filed separately with the 
 Securities and
Exchange Commission. Asterisks denote omissions. 
 LICENSE AGREEMENT 

THIS LICENSE AGREEMENT (the “AGREEMENT”) made and entered into this tenth day of January, 2000, by and between DUKE UNIVERSITY,
a North Carolina not-for-profit corporation, (hereinafter called “DUKE”), having its principal office at Durham, North Carolina 27708, and MERIX BIOSCIENCE, INC., a Delaware corporation organized under the laws of Delaware (hereinafter
called “MERIX”), having a mailing address at P.O. Box 14509, Research Triangle Park, North Carolina 27709. 
 WHEREAS,
Eli Gilboa and Smita Nair are inventors of an invention [the “1101 INVENTION” hereinafter] described in Duke Office of Science and Technology File #1101 and in related patent applications defined hereinafter; and 

WHEREAS, Eli Gilboa, Smita Nair, and David Boczkowski are inventors of an invention [the “1215 INVENTION” hereinafter]
described in Duke Office of Science and Technology File #1215 and in related patent applications defined hereinafter; and 

WHEREAS, DUKE has the right to grant licenses to the 1101 INVENTION and to the 1215 INVENTION under PATENT RIGHTS (as hereinafter
defined), and wishes to have the inventions covered by the PATENT RIGHTS utilized in the public interest; and 
 WHEREAS, DUKE
represents that it is the sole owner of the entire right, title and interest in and to said inventions and PATENT RIGHTS; and 

WHEREAS, DUKE granted to Dendritix, Inc. in an Option Agreement made the eighteenth day of December 1998 an option to obtain an exclusive
license to the 1101 INVENTION and also to the 1215 INVENTION under the terms and conditions specified hereinafter; and 

WHEREAS, Dendritix, Inc. has changed its corporate name to Merix Bioscience, Inc.; and 

WHEREAS, MERIX has informed DUKE that it wishes to exercise its exclusive option to license the 1215 INVENTION and the 1101 INVENTION
under the terms and conditions specified hereinafter; and 
 WHEREAS, MERIX represents that it intends to develop and
commercialize the Patents Rights so that products made under the PATENT RIGHTS shall become available to the public; and 
 NOW
THEREFORE, in consideration of the premises and the faithful performance of the covenants herein contained, IT IS AGREED: 

ARTICLE 1 - DEFINITIONS 
 1.01 - For the purposes of this AGREEMENT, and solely for that purpose, the terms and phrases set forth hereinafter in capital letters shall be defined as follows: 

 

	 	a.	“FIELD” shall mean all uses of the know-how and patent rights, cell lines, substances and material produced by cell lines and included in PATENT RIGHTS,
specifically including, without limitation, research and development, diagnosis, prevention, therapy, and monitoring of all human and animal diseases or disorders. 

  
 - 1 -

	 	b.	“PATENT RIGHTS” shall mean all U.S. and foreign Patent Applications filed to protect the 1101 INVENTION or the 1215 INVENTION and any patent now issued or
hereafter issuing on any such patent application, substitutes, continuations, extensions, renewals, reissues, reexaminations, additions, continuations-in-part, divisionals, or reissues thereof and any patent revalidations, registrations,
supplementary protection certificates, patents of importation or cautionary notices thereof in connection with the 1101 INVENTION or 1215 INVENTION. As of the EFFECTIVE DATE of this AGREEMENT, PATENT RIGHTS related to the 1101 INVENTION include
[**]. As of the EFFECTIVE DATE of this AGREEMENT, PATENT RIGHTS related to the 1215 INVENTION include [**]. 

  

	 	c.	“Know-How” shall mean any research information, technical information, technical data or other confidential information not in the public domain made or that
may be made by one of the inventors of the 1101 INVENTION or the 1215 INVENTION and/or one of them and others working under the supervision of one of them, while students or employees of DUKE prior to or during the term of this AGREEMENT, which
relate to and are necessary for the practice of the PATENT RIGHTS in the FIELD. For avoidance of doubt, Know-How shall include all unpatented and unpatentable inventions, technology, cell lines, biological materials, compounds, probes, sequences,
and methods necessary for the practice of the PATENT RIGHTS under this AGREEMENT. Know-How shall not, however, include any such materials or information or any uses of such materials and information that DUKE cannot provide to MERIX on either an
exclusive or non-exclusive basis because of other legal obligations of DUKE pursuant to sponsored research, clinical research, material transfer, confidentiality or other agreements. 

 

	 	d.	“VALID CLAIM” means a claim of an issued patent which has not lapsed or become abandoned or been declared invalid or unenforceable by a court of competent
jurisdiction or an administrative agency for which there is no right of appeal or for which the right of appeal is waived. 

  

	 	e.	“LICENSED PRODUCT” shall mean any product which is produced or sold by MERIX that utilizes the KNOW-HOW or that infringes one or more VALID CLAIMS of the
PATENT RIGHTS, and which is intended for use in, or is used in, the FIELD. 

  

	 	f.	“NET SALES” shall mean the total invoiced sales of LICENSED PRODUCTS sold by MERIX, less the following sums actually paid or credited by MERIX as shall be
detailed in MERIX’s reports made pursuant to Section 5.02 of this AGREEMENT: 

  

	 	(a)	trade, quantity or cash discounts or commissions allowed in amounts customary in the trade; 

  
 - 2 -

	 	(b)	any tax, excise or other governmental charge upon or measured by the production, sale, transportation, delivery or use and duties imposed on the import of LICENSED
PRODUCTS included in such amount; 

  

	 	(c)	outbound transportation charges prepaid or allowed on the cost of shipping to customers, if any; and 

 

	 	(d)	credits or allowances, if given or made for LICENSED PRODUCTS, price adjustments, returns, rejections, recalls or destructions (voluntarily made by or requested or made
by an appropriate government agency, subdivision or department) of LICENSED PRODUCTS previously delivered. 

LICENSED PRODUCTS used by MERIX for its own use in the FIELD, LICENSED PRODUCTS sold to Affiliates, and internal sales for use in service
businesses in arms length transactions shall be considered to be NET SALES for purposes of computing royalty obligations, except such LICENSED PRODUCT used for non-revenue producing activity such as promotional items or field trials shall not be
considered to be NET SALES. 
  

	 	g.	“AFFILIATE” shall mean any entity which controls, is controlled by or is under common control with MERIX. An entity shall be regarded as in control of another
entity if it owns or controls more than fifty percent (50%) of the voting power of the entity. 

  

	 	h.	“FOUNDERS” shall mean H. Kim Lyerly, Eli Gilboa, Clay Smith, and Bruce Sullenger, the scientific founders of MERIX, and “FOUNDER” shall mean any of
these individuals. 

  

	 	i.	“OPTIONED INVENTION” shall mean an invention having been made solely or jointly by a FOUNDER while the FOUNDER was employed by DUKE subsequent to the
EFFECTIVE DATE and during the term of this AGREEMENT in the field of autoimmune diseases or disorders, infectious diseases or cancer in humans or animals and useful for: (i) active and/or adoptive immunological intervention intended for therapy
or prevention; (ii) monitoring of immunological parameters for diagnosis, therapy or the development of candidate interventions; or (iii) discovery of new antigens for diagnosis, monitoring or therapy; provided, however, that such an
invention shall not be an OPTIONED INVENTION if DUKE is legally unable to grant MERIX an option for an exclusive license (or if an exclusive license is not legally possible, a non-exclusive license) to such invention under the terms of sponsored
research, clinical research, material transfer, confidentiality or other agreements with third parties; and provided furthermore that any invention related to stem cells shall not be an OPTIONED INVENTION. Nothing in the foregoing definition of
OPTIONED INVENTION shall be construed as limiting the right of FOUNDERS or DUKE to enter into sponsored research, clinical research, material transfer, confidentiality, or other agreements granting intellectual property rights to any other party,
not for profit or for profit, provided that such agreements do not conflict with the exclusive license to PATENT RIGHTS and KNOW-HOW granted in Article 2 herein. 

  
 - 3 -

	 	j.	“FOUNDERS’ SHARES” shall mean common stock of MERIX issued or reserved for issue by MERIX prior to closing a round of equity financing with outside
investors. The fair market value and price of FOUNDERS’ SHARES shall be deemed to be one cent [$0.01] per share. DUKE and MERIX agree that all FOUNDERS’ SHARES issued shall be dilutable to the same extent upon each stage of subsequent
financing of MERIX and that the total number of FOUNDERS’ SHARES, issued or reserved for issuance, will be two million five hundred thousand [2,500,000] shares. 

 

	 	k.	“EFFECTIVE DATE” shall mean January 10, 2000. 

 ARTICLE 2 - LICENSE 
 2.01 - DUKE hereby grants to the MERIX and MERIX
hereby accepts from DUKE, upon the terms and conditions herein specified, an exclusive worldwide license under the PATENT RIGHTS and KNOW-HOW to make, have made, use, import, offer to sell, sell, offer to provide and provide LICENSED PRODUCTS. Such
license is worldwide to the full end of the term as provided in Article 11.01 hereof, unless sooner terminated as hereinafter provided. DUKE hereby represents that it has the full right and authority to enter into this AGREEMENT, to grant the
licenses provided herein and to perform its other obligations hereunder. 
 2.02 - MERIX shall have the right to grant
sub-licenses. Any such sub-licenses shall be subject to terms of this AGREEMENT. Royalties paid to DUKE for NET SALES of LICENSED PRODUCTS by sublicensees shall be equal to the royalties that would have been paid to DUKE if LICENSED PRODUCTS were
sold directly by MERIX. The terms of any non-cash sub-licenses will be negotiated by DUKE and MERIX. MERIX agrees to be responsible for the payment to DUKE of royalties on funds received by MERIX from its sublicensees and for using commercially
reasonable efforts to enforce the terms of the sublicense agreements. If, for any reason, this AGREEMENT is terminated, MERIX agrees to assign all such sublicenses directly to DUKE. 

2.03 - It is agreed that, notwithstanding any provisions herein, DUKE is free to use the 1101 INVENTION, the 1215 INVENTION and PATENT
RIGHTS for its own non-commercial educational, teaching, research and clinical purposes without restriction and without payment of royalties or other fees. 
 2.04 - Nothing in this AGREEMENT shall be construed to grant to DUKE any rights in the inventions, discoveries, technology, patent rights or other intellectual property developed by or for MERIX or its
AFFILIATES or sub-licensees and which are not covered by the PATENT RIGHTS or KNOW-HOW. 

  
 - 4 -

 2.05 - Within [**] days following the execution of this AGREEMENT and thereafter during the
period of this AGREEMENT, DUKE agrees to provide MERIX with copies of all technical know-how it may have or later obtain relative to the PATENT RIGHTS or KNOW-HOW, and copies of any and all patents or patent applications owned or controlled by DUKE
covering the PATENT RIGHTS or KNOW-HOW or the use of the PATENT RIGHTS or KNOW-HOW or processes for the manufacture of the LICENSED PRODUCTS, including all Patent Office actions received and amendments filed, if any, relative thereto. 

ARTICLE 3 - OPTION 
 3.01 - DUKE hereby grants to MERIX an exclusive option to obtain an exclusive, worldwide, royalty bearing license to all new OPTIONED INVENTIONS. DUKE shall notify MERIX within [**] of the date that DUKE
learns that an OPTIONED INVENTION has been made. MERIX shall then have a period of [**] days [the “OPTION PERIOD”] to inform DUKE in writing that MERIX wishes to exercise its option to negotiate a license to the OPTIONED INVENTION. If
MERIX does not notify DUKE that it wishes to exercise its option within the OPTION PERIOD, or if MERIX informs DUKE that it does not wish to exercise its option, the option will expire at the end of the OPTION PERIOD, and DUKE will be free to
dispose of the OPTIONED INVENTIONS in DUKE’s sole discretion. If MERIX notifies DUKE in writing during the OPTION PERIOD that MERIX wishes to exercise its option, DUKE and MERIX will negotiate in good faith for [**] days from the date that DUKE
receives notification from MERIX [the “NEGOTIATION PERIOD”] to conclude a license agreement for the OPTIONED INVENTION on commercially reasonable terms and substantially in accordance with Exhibit A hereto. If the parties cannot
agree on terms by the end of the NEGOTIATION PERIOD, DUKE will be under no obligation to continue negotiations and will be free to dispose of the OPTIONED INVENTION on terms no more favorable than offered to MERIX. 

ARTICLE 4 - CONSIDERATION 
 4.01 - As consideration for the rights granted by DUKE in this AGREEMENT, MERIX shall transfer to DUKE upon execution of this AGREEMENT, ownership of five hundred thousand [500,000] fully vested,
non-voting FOUNDERS’ SHARES, equal to twenty percent [20%] of the total FOUNDERS’ SHARES issued or reserved for issuance by MERIX. At the time that MERIX closes on the sale of capital stock to the public through a registration statement
registered under the Securities Act of 1933, as amended, DUKE’s shares will convert to voting shares of common stock. 

4.02 - DUKE shall be entitled to have one person reasonably acceptable to MERIX attend all meetings of the Board of Directors of MERIX as
an observer for a period of [**] years from the EFFECTIVE DATE of this AGREEMENT. 

  
 - 5 -

 4.03 - As further consideration for the rights granted by DUKE in this AGREEMENT, at the
times and in the manner set forth hereinafter, MERIX shall pay to DUKE a royalty on NET SALES of LICENSED PRODUCTS. Such royalty shall be at the rate of [**] percent ([**]%) of NET SALES of LICENSED PRODUCTS sold by MERIX, by AFFILIATES, or by
sublicensees; provided, however, that MERIX shall not be obliged to pay a total royalty on any LICENSED PRODUCT to all parties in excess of [**] percent ([**]%) of NET SALES. In the event that MERIX’s total royalty obligation on a LICENSED
PRODUCT exceeds [**]percent ([**]%) the amount of royalty paid to all parties will be decreased proportionately so that the total royalty obligation is reduced to [**] percent ([**]%); however, in no event shall the royalty paid to DUKE be less than
[**] percent ([**]%). For avoidance of doubt, the parties agree that any other royalties due to DUKE for the LICENSED PRODUCTS based on other agreements between DUKE and MERIX shall (including the license for the inventions described in Duke Office
of Science and Technology File #[**]) be included in the calculation of total royalties set forth in this paragraph. 
 4.04 -
MERIX will pay to DUKE a minimum annual royalty of [**] dollars ($[**]) per year beginning the calendar year that begins on the second January 1 after the earlier of (1) the approval of the first LICENSED PRODUCT by the FDA or a comparable
regulatory authority in a foreign country or (2) the first sale of a LICENSED PRODUCT that does not require FDA approval. Any payments made by MERIX pursuant to Section 4.03 hereof for a particular calendar year shall be credited to the
minimum annual royalty for such calendar year. 
 4.05 - All consideration paid to DUKE under Article 4.01 will be allocated as
follows: [**] percent [[**]%] as consideration for the license granted to the 1215 INVENTION and related PATENT RIGHTS under Article 2 herein, [**] percent [[**]%] as consideration for the license granted to the 1101 INVENTION and related PATENT
RIGHTS under Article 2 herein, and [**] percent [[**]%] as consideration for the option granted under Article 3 herein. 

ARTICLE 5 - RECORDS AND REPORTS 
 5.01 - MERIX shall render to DUKE prior to February 28th of each year a written account of progress made toward fulfillment of any due diligence requirements and commercialization of PATENT RIGHTS
pursuant to Article 6. 
 5.02 - MERIX shall render to DUKE prior to February 28th and August 31st of each year a written account of the NET SALES of LICENSED PRODUCTS
subject to royalty hereunder made during the prior six month period ending December 31st and June 30th, respectively, and shall simultaneously pay to DUKE the royalties due on such NET SALES in United States Dollars. Reports tendered shall include the calculation of royalties by LICENSED PRODUCT by
country in substantially the format provided in Appendix A hereto]. Minimum annual royalties, if any, which are due DUKE for any calendar year, shall be paid by MERIX along with the written report due on February 28th of each year. 

5.03 - MERIX will make all payments on or before the date required by the terms of this AGREEMENT, or within [**] days of any invoice
date on invoices received from DUKE. If LICENSEE has not paid any amount due to DUKE in accordance with this Article, DUKE shall increase the amount due (in US Dollars) by an annual percentage rate equal to [**]%. Such increase(s) shall compound
monthly until such time as the LICENSEE has met the full financial obligation due at the time of the next payment or invoice due date. 

  
 - 6 -

 5.04 - MERIX shall keep full, true and accurate books of accounts and other records
containing all particulars which may be necessary to properly ascertain and verify the royalties payable by it hereunder. Upon DUKE’s request, MERIX shall permit an independent Certified Public Accountant selected by DUKE (except one to whom
MERIX has some reasonable objection) to have access during ordinary business hours to such of MERIX’s records as may be necessary to determine, in respect of any quarter ending not more than [**] years prior to the date of such request, the
correctness of any report and/or payment made under this AGREEMENT. Such Certified Public Accountant shall execute a written nondisclosure agreement reasonably acceptable to MERIX. 

5.05 - During the term of this AGREEMENT, representatives of DUKE will meet with representatives of MERIX at times and places mutually
agreed upon to discuss the progress and results, as well as ongoing plans, with respect to the evaluation and development of the PATENT RIGHTS licensed to MERIX; provided, however, that should DUKE’s personnel be required by MERIX to consult
with MERIX outside of Durham County, North Carolina, MERIX will reimburse reasonable travel and living expenses incident thereto. 
 ARTICLE 6 - DUE DILIGENCE REQUIREMENTS 
 6.01 - MERIX shall use reasonable
commercial diligence in performing research and development to bring LICENSED PRODUCTS to market through a thorough, vigorous, and diligent program for exploitation of the PATENT RIGHTS, to develop manufacturing capabilities, and to continue active,
diligent marketing efforts for LICENSED PRODUCTS throughout the term of this AGREEMENT, and to vigorously sublicense PATENT RIGHTS for applications MERIX will not pursue throughout the life of this AGREEMENT. 

6.02 - In addition, MERIX shall raise at least ONE MILLION DOLLARS [$1,000,000] in equity investment prior to or within three months of
the EFFECTIVE DATE of this AGREEMENT. 
 6.03 - DUKE may terminate this AGREEMENT or convert this AGREEMENT to a non-exclusive
AGREEMENT if MERIX fails to meet any of the commercialization milestones set forth in Article 6.01 or 6.02 and MERIX has failed to cure such failure within [**] days after receiving written notice from DUKE of such failure. 

ARTICLE 7 - PATENTS 
 7.01 - Upon execution of this License Agreement, MERIX will assume the primary responsibility for applying for, seeking prompt issuance of, and maintaining the Patent Rights during the term of the
Agreement. MERIX shall diligently and in a timely manner provide DUKE with copies of all documents relating to the prosecution, maintenance, and validity of the PATENT RIGHTS. MERIX shall consult with DUKE in such prosecution and maintenance, and
shall diligently seek strong and broad claims under the Patent Rights and shall not abandon prosecution of any patent application or any of the claims of the Patent Rights without first notifying DUKE in a timely manner of MERIX’s intention and
reason therefor, and providing DUKE with reasonable opportunity to assume responsibility for prosecution and maintenance of the patents. 

  
 - 7 -

 7.02 - MERIX shall be responsible for and pay all costs and expenses incurred during the
term of this Agreement, for the preparation, filing, prosecution, issuance and maintenance of the Patent Rights. MERIX shall not allow Patent Rights to become abandoned due to nonpayment of fees without first affording DUKE the opportunity to assume
responsibility for further costs and expenses incurred relating to said Patent Rights. 
 7.03 - In the event that DUKE assumes
responsibility for prosecution and maintenance of the Patent Rights pursuant to Section 7.01 or 7.02 above, MERIX shall provide reasonable technical assistance to DUKE in the further prosecution of the Patent Rights. 

7.04 - In the event that this Agreement is terminated pursuant to Article 11 herein, the sole responsibility for applying for, seeking
prompt issuance of, and maintaining the Patent Rights shall revert to the DUKE, and DUKE shall pay expenses subsequently incurred for the preparation, filing, prosecution, issuance and maintenance of the Patent Rights. In the event that
responsibility for patent prosecution reverts to DUKE as specified in this section 7.04, MERIX shall, at its own expense, transfer all pertinent documents and materials related to the PATENT RIGHTS to DUKE in a timely manner. 

ARTICLE 8 - INFRINGEMENT BY THIRD PARTIES 
 8.01 - Upon learning of the infringement of PATENT RIGHTS by a third party, the party learning of such infringement shall promptly inform the other party in writing of that fact along with any evidence
available pertaining to the infringement. MERIX may at its own expense take whatever steps are necessary to stop the infringement and recover damages. In such case, MERIX will keep DUKE informed of the steps taken and the progress of any legal
actions taken. MERIX will pay to DUKE royalties pursuant to Article 4.03 on any such damages recovered as consideration for lost sales of LICENSED PRODUCTS that are in excess of legal expenses incurred by MERIX in enforcing its PATENT RIGHTS. If
MERIX does not undertake, within [**] days of notice, to enforce the PATENT RIGHTS against the infringing party, DUKE shall have the right, at its own expense to take whatever steps are necessary to stop the infringement and recover damages, and
shall be entitled to retain damages so recovered (after reimbursing MERIX for any of its expenses in cooperating with DUKE in prosecuting such infringement). 
 ARTICLE 9 - GOVERNMENT CLEARANCE AND EXPORT 
 9.01 - MERIX agrees to use
its best efforts to have the LICENSED PRODUCTS cleared for marketing and sale in those countries in which MERIX intends to sell LICENSED PRODUCTS by the responsible government agencies requiring such clearance. Where such clearance requires payment
of taxes or fees, MERIX shall maintain full responsibility for that payment, which shall not be creditable against any other amounts due under this AGREEMENT. To accomplish said clearances at the earliest possible date, MERIX agrees to file,
according to the usual practice of MERIX, any necessary data with said government agencies. 
 9.02 - This AGREEMENT is subject
to all of the United States laws and regulations controlling the export of technical data, computer software, laboratory prototypes and other commodities and technology. 

  
 - 8 -

 ARTICLE 10 - PUBLICATION 

10.01 - MERIX agrees that the right of publication of the 1101 INVENTION and of the 1215 INVENTION and information in related PATENT
RIGHTS shall reside in the inventors and other staff of DUKE. DUKE shall use reasonable efforts to provide MERIX a review copy of such publications [**] days in advance of submission for publication or public disclosure, but such prior review by
MERIX will be in no way construed as a right to restrict such publication. Such review shall be granted solely so that DUKE and MERIX can perfect patent protection prior to public disclosure. MERIX shall also have the right to publish and/or
co-author any publication on the 1101 INVENTION and the 1215 INVENTION based upon data developed by MERIX. 
 ARTICLE 11 -
DURATION AND TERMINATION 
 11.01 - This AGREEMENT shall become effective upon the EFFECTIVE DATE, and unless sooner
terminated in accordance with any of the provisions herein, shall remain in full force and effect for the longer of: (i) the life of the last-to-expire of the patents included in the PATENT RIGHTS or any patents issued on KNOW-HOW; or (ii), so
long as one or more FOUNDERS is employed by DUKE, ten (10) years from the EFFECTIVE DATE hereof. Upon the expiration of this AGREEMENT, DUKE shall grant MERIX an exclusive, worldwide, fully paid license, with the right to grant sub-licenses,
under the KNOW-HOW to make, have made, use, import, offer to sell, sell, offer to provide and provide LICENSED PRODUCTS. 

11.02 - MERIX may terminate this AGREEMENT by giving DUKE written notice at least three (3) months prior to such termination, and
thereupon terminate the manufacture, use or sale of LICENSED PRODUCTS. 
 11.03 - Either party may immediately terminate this
AGREEMENT for fraud, willful misconduct, or illegal conduct of the other party that materially adversely affects such party upon written notice of same to that other party. Except as provided above, if either party fails to fulfill any of its
material obligations under this AGREEMENT, the non-breaching party may terminate this AGREEMENT, upon written notice to the breaching party, as provided below. Such notice must contain a full description of the event or occurrence constituting a
breach of this AGREEMENT. The party receiving notice of the breach shall submit a plan to cure such breach to the non-defaulting party within [**] days of receipt of such notice. The plan shall be subject to the reasonable acceptance, rejection or
modification by the non-defaulting party within [**] days of receipt of the plan. The defaulting party shall have the opportunity to cure that breach in accordance with the terms of the accepted plan. If the breach is not cured within that time, the
termination will be effective as of the end of the cure period set forth in the accepted plan. A party’s ability to cure a breach will apply only to the first two breaches properly noticed under the terms of this AGREEMENT, regardless of the
nature of those breaches. Any subsequent breach by that party will entitle the other party to terminate this AGREEMENT upon proper notice. 
 11.04 - Upon the termination of this AGREEMENT, MERIX may notify DUKE of the amount of LICENSED PRODUCTS MERIX then has on hand and MERIX shall then have a license to sell that amount of LICENSED
PRODUCTS, but no more, provided MERIX shall pay the royalty thereon at the rate and at the time provided for herein. 

  
 - 9 -

 11.05 - If during the term of this Agreement, MERIX shall become bankrupt or insolvent or if
the business of MERIX shall be placed in the hands of a receiver or trustee, whether by the voluntary act of MERIX or otherwise, or if MERIX shall cease to exist as an active business, this Agreement shall immediately terminate as though with MERIX
breach, and DUKE shall have all the remedies and rights available to it for termination with cause; provided, however, that this provision shall not apply to a reorganization of MERIX under Chapter 11 of the United States Bankruptcy Code.

 ARTICLE 12 - LAW TO GOVERN 
 12.01 - This AGREEMENT shall be construed and enforced in accordance with the laws of the State of North Carolina. 
 ARTICLE 13 - NOTICES 
 13.01 - Notice hereunder shall be deemed sufficient
if personally delivered, if given by registered mail, postage prepaid, or by national overnight courier, charges prepaid, and in each instance addressed to the party to receive such notice at the address given below, or such other address as may
hereafter be designated by notice in writing. 
  

			
	DUKE	 	MERIX
		
	Office of Science and Technology	 	P.O. Box 14509
	Duke University	 	Research Triangle Park, NC 27709
	Room 230, North Building	 	ATTENTION: CEO
	Box 90083	 	
	Durham, NC 27708	 	
		
	cc: Office of the University Counsel	 	cc: Fred D. Hutchison, Esquire
	Duke University Medical Center	 	Hutchison & Mason PLLC
	DUMC Box 3024	 	Suite 100
	2400 Pratt Street, Suite 4000	 	3110 Edwards Mill Road
	Durham NC 27710	 	Raleigh NC 27612

 13.02 - Information and transactions exchanged between the parties in relation to financial consideration
contemplated under this AGREEMENT, including but not limited to royalty reports and payments, shall be tendered to the following offices of each party respectively: 
  

			
	DUKE	 	MERIX
	Office of Science and Technology	 	P.O. Box 14509
	Attn.: Financial Administrator	 	Research Triangle Park, NC 27709
	Room 230, North Building	 	ATTENTION: CEO
	Box 90083	 	
	Durham NC 27708	 	

  
 - 10 -

 ARTICLE 14 - ASSIGNMENT 

14.01 - This AGREEMENT shall be binding upon and inure to the benefit of the respective successors and assigns of the parties hereto.
However, MERIX may not assign its rights in this AGREEMENT without approval by DUKE, such approval not to be unreasonably withheld; provided, however, that no such approval shall be required from DUKE if this AGREEMENT is assigned in connection with
the sale of all or substantially all of the assets or stock of MERIX, whether by merger, acquisition or otherwise. 
 ARTICLE
15 - INDEMNITY, INSURANCE, REPRESENTATIONS, STATUS 
 15.01 - MERIX agrees to indemnify, hold harmless and defend DUKE, its
officers, employees, and agents, against any and all claims, suits, losses, damages, costs, fees, and expenses asserted by third parties, both government and non-government, resulting from or arising out of the exercise of the license granted under
this AGREEMENT. MERIX shall not be responsible for the negligence or intentional wrong doing of DUKE. 
 15.02 - MERIX shall
maintain in force at its sole cost and expense, with reputable insurance companies, general liability insurance and products liability insurance coverage in amounts customary for companies similarly situated in the same industry. DUKE shall have the
right to ascertain from time to time that such coverage exists, such right to be exercised in a reasonable manner. In lieu of said coverage, DUKE agrees to consider the existence of an adequate self-insurance program as an acceptable alternative.

 15.03 - NOTHING IN THIS AGREEMENT SHALL BE DEEMED TO BE A REPRESENTATION OR WARRANTY BY DUKE OF THE VALIDITY OF ANY OF THE
PATENTS OR THE ACCURACY, SAFETY, EFFICACY, OR USEFULNESS, FOR ANY PURPOSE, OF ANY PATENT RIGHTS. DUKE SHALL HAVE NO OBLIGATION, EXPRESS OR IMPLIED, TO SUPERVISE, MONITOR, REVIEW OR OTHERWISE ASSUME RESPONSIBILITY FOR THE PRODUCTION, MANUFACTURE,
TESTING, MARKETING OR SALE OF ANY LICENSED PRODUCT, AND DUKE SHALL HAVE NO LIABILITY WHATSOEVER TO MERIX OR ANY THIRD PARTIES FOR OR ON ACCOUNT OF ANY INJURY, LOSS, OR DAMAGE, OF ANY KIND OR NATURE, SUSTAINED BY, OR ANY DAMAGE ASSESSED OR ASSERTED
AGAINST, OR ANY OTHER LIABILITY INCURRED BY OR IMPOSED UPON MERIX OR ANY OTHER PERSON OR ENTITY, ARISING OUT OF OR IN CONNECTION WITH OR RESULTING FROM: 
  

	 	a.	the production, use, or sale of any LICENSED PRODUCT; 

  

	 	b.	the use of any PATENT RIGHTS by MERIX or its sublicensees; or 

  

	 	c.	any advertising or other promotional activities by MERIX with respect to any of the foregoing. 

15.04 - Neither party hereto is an agent of the other party for any purpose whatsoever. 

  
 - 11 -

 ARTICLE 16 - USE OF A PARTY’S NAME 

16.01 - Neither party will, without the prior written consent of the other party: 

 

	 	a.	use in advertising, publicity or otherwise, any trade-name, personal name, trademark, trade device, service mark, symbol, or any abbreviation, contraction or simulation
thereof owned by the other party; or 

  

	 	b.	represent, either directly or indirectly, that any product or service of the other party is a product or service of the representing party or that it is made in
accordance with or utilizes the information or documents of the other party. 

 ARTICLE 17 - SEVERANCE, WAIVER
AND ALTERATION 
 17.01 - Each clause of this AGREEMENT is a distinct and severable clause and if any clause is deemed
illegal, void or unenforceable, the validity, legality or enforceability of any other clause or portion of this AGREEMENT will not be affected thereby. 
 17.02 - The failure of a party in any instance to insist upon the strict performance of the terms of this AGREEMENT will not be construed to be a waiver or relinquishment of any of the terms of this
AGREEMENT, either at the time of the party’s failure to insist upon strict performance or at any time in the future, and such terms will continue in full force and effect. 

17.03 - Any alteration, modification, or amendment to this AGREEMENT must be in writing and signed by both parties. 

ARTICLE 18 - CONFIDENTIALITY 
 18.01 - During the term of this AGREEMENT and for a period of [**] years following the expiration of termination of this AGREEMENT, DUKE and MERIX each agree to treat any confidential information
disclosed to it by the other party to this AGREEMENT with reasonable care and to avoid disclosure of such information to any other person, firm or corporation, except AFFILIATES, and either party shall be liable for unauthorized disclosure or
failure to exercise such reasonable care. Neither party shall have an obligation, with respect to confidential information disclosed to it, or any part thereof, which: 
 (a) is already known to the party at the time of the disclosure; 
 (b) becomes
publicly known without the wrongful act or breach of this AGREEMENT by the party; 
 (c) is rightfully received by the party
from a third party on a non-confidential basis; 
 (d) is subsequently and independently developed by employees of the party who
had no knowledge of the information, as verified by written records; or 
 (e) is approved for release by written authorization
of the party disclosing the information. 

  
 - 12 -

 18.02 - DUKE and MERIX agree that any information to be treated as confidential information
under this Article 18 must be disclosed in writing or in another tangible medium and must be clearly marked “CONFIDENTIAL”. Information disclosed orally must be summarized and reduced to writing and communicated to the other party within
[**] days, and the other party agrees that such disclosed information shall be deemed confidential. 
 18.03 - Notwithstanding
the foregoing, MERIX shall have the right to use and disclose any Confidential Information related to the PATENT RIGHTS and KNOW-HOW to investors, prospective investors, employees and agents with a need to know, collaborators, prospective
collaborators and other third parties in the chain of manufacturing and distribution provided that MERIX obtains from such parties written confidentiality agreements the provisions of which are at least as strenuous as those provided in this Article
18. If a party refuses to execute a written confidentiality agreement, MERIX may request from DUKE that such requirement be waived, such consent to waiver not to be unreasonably withheld by DUKE. 

ARTICLE 19 - TRANSFER OF MATERIALS 
 19.01 - Any transfer of materials between DUKE and MERIX in connection with this AGREEMENT shall be made under the terms of the Master Materials Transfer Agreement [MMTA], said MMTA being incorporated in
its entirety as Appendix B of the present AGREEMENT. 
 ARTICLE 20 - TITLES 

20.01 - All titles and article headings contained in this AGREEMENT are inserted only as a matter of convenience and reference. They do
not define, limit, extend or describe the scope of this AGREEMENT or the intent of any of its provisions. 
 ARTICLE 21 -
ENTIRE UNDERSTANDING 
 21.01 - This AGREEMENT represents the entire understanding between the parties with respect to the
subject matter hereof, and supersedes all other agreements, express or implied, between the parties concerning the 1101 INVENTION, the 1215 INVENTION, and PATENT RIGHTS. 
 REMAINDER OF THIS PAGE LEFT BLANK INTENTIONALLY. 
 SIGNATURES ON NEXT PAGE.

  
 - 13 -

 IN WITNESS WHEREOF, the parties have caused these presents to be executed in
duplicate as of the date and year first above written. 
  

					
	SEAL	 	DUKE UNIVERSITY
			
		 	By:	 	 /s/ Robert Taber

		 		 	  Robert Taber
		 		 	  Director, Office of Science & Technology
			
		 	Date:	 	 1-10-2000

		
	SEAL	 	MERIX BIOSCIENCE, INC.
			
		 	By:	 	 /s/ John C. Irick

		 	Title:	 	 Chief Executive Officer

		 	Date:	 	 1-10-2000

  
 - 14 -

 Exhibit A to License Agreement for 1101 INVENTION and 1215 INVENTION 

LICENSE AGREEMENT 
 THIS LICENSE AGREEMENT (the “AGREEMENT”) made and entered into this              day of
            , 20    , by and between DUKE UNIVERSITY, a North Carolina not-for-profit corporation, (hereinafter called “DUKE”), having its principal office at
Durham, North Carolina 27708, and MERIX BIOSCIENCE, INC. a Delaware corporation organized under the laws of Delaware (hereinafter called “MERIX”), having a mailing address at P.O. Box 14509, Research Triangle Park, North Carolina 27709.

 WHEREAS,
                                         
                                        are inventors
of an invention [the “             INVENTION” hereinafter] described in Duke Office of Science and Technology File
#             and in related patent applications defined hereinafter; and 
 WHEREAS, DUKE has the right to grant licenses to the              INVENTION under PATENT RIGHTS (as hereinafter defined), and wishes to have the
inventions covered by the PATENT RIGHTS utilized in the public interest; and 
 [WHEREAS, the
             Invention was made with U.S. Government support and, notwithstanding any use of descriptive terms within this AGREEMENT such as “exclusive”, the U. S. Government has
certain rights in the              Invention under 37 C.F.R. Section 401; and] 
 WHEREAS, DUKE represents that it is the sole owner of the entire right, title and interest in and to said inventions and PATENT RIGHTS[, subject to the U.S. Government’s rights specified above]; and

 WHEREAS, MERIX represents that it intends to develop and commercialize the Patents Rights so that products made under the
PATENT RIGHTS shall become available to the public. 
 NOW THEREFORE, in consideration of the premises and the faithful
performance of the covenants herein contained, IT IS AGREED: 
 ARTICLE 1 - DEFINITIONS 

1.01 - For the purposes of this AGREEMENT, and solely for that purpose, the terms and phrases set forth hereinafter in capital letters
shall be defined as follows: 
  

	 	a.	“FIELD OF USE 1” shall mean the use of the know-how and patent rights, cell lines, substances and material produced by cell lines and included in PATENT
RIGHTS in the field of autoimmune diseases or disorders, infectious diseases or cancer in humans or animals and useful for: (i) active and/or adoptive immunological intervention intended for therapy or prevention; (ii) monitoring of
immunological parameters for diagnosis, therapy or the development of candidate interventions; or (iii) discovery of new antigens for diagnosis, monitoring or therapy. 

  
 - 1 -

	 	b.	“PATENT RIGHTS” shall mean all U.S. and foreign patent applications filed to protect the
             INVENTION and any patent now issued or hereafter issuing on any such patent application, substitutes, continuations, extensions, renewals, reissues, reexaminations, additions,
continuations-in-part, divisionals, or reissues thereof and any patent revalidations, registrations, supplementary protection certificates, patents of importation or cautionary notices thereof in connection with the
             Invention. As of the EFFECTIVE DATE of this AGREEMENT, PATENT RIGHTS related to the              INVENTION consist
of the following: [To Be Completed] 

  

	 	c.	“Know-How” shall mean any research information, technical information, technical data or other confidential information not in the public domain made or that
may be made by one of the inventors of the              INVENTION and/or one of them and others working under the supervision of one of them, while students or employees of DUKE prior to or
during the term of this AGREEMENT, which relate to and are necessary for the practice of the PATENT RIGHTS. For avoidance of doubt, Know-How shall include all unpatented and unpatentable inventions, technology, cell lines, biological materials,
compounds, probes, sequences, and methods necessary for the practice of the PATENT RIGHTS under this AGREEMENT. Know-How shall not, however, include any such materials or information or any uses of such materials and information that DUKE cannot
provide to MERIX on either an exclusive or non-exclusive basis because of other legal obligations of DUKE pursuant to sponsored research, clinical research, material transfer, confidentiality or other agreements. 

 

	 	d.	“VALID CLAIM” means a claim of an issued patent which has not lapsed or become abandoned or been declared invalid or unenforceable by a court of competent
jurisdiction or an administrative agency for which there is no right of appeal or for which the right of appeal is waived. 

  

	 	e.	“LICENSED PRODUCT” shall mean any product which is produced or sold by MERIX that utilizes the KNOW-HOW or that infringes one or more VALID CLAIMS of the
PATENT RIGHTS, and which is intended for use in, or is used in, the FIELD. 

  

	 	f.	“NET SALES” shall mean the total invoiced sales of LICENSED PRODUCTS sold by MERIX, less the following sums actually paid or credited by MERIX as shall be
detailed in MERIX’s reports made pursuant to Section 5.02 of this AGREEMENT: 

  

	 	(a)	trade, quantity or cash discounts or commissions allowed in amounts customary in the trade; 

 

	 	(b)	any tax, excise or other governmental charge upon or measured by the production, sale, transportation, delivery or use and duties imposed on the import of LICENSED
PRODUCTS included in such amount; 

  
 - 2 -

	 	(c)	outbound transportation charges prepaid or allowed on the cost of shipping to customers, if any; and 

 

	 	(d)	credits or allowances, if given or made for LICENSED PRODUCTS, price adjustments, returns, rejections, recalls or destructions (voluntarily made by or requested or made
by an appropriate government agency, subdivision or department) of LICENSED PRODUCTS previously delivered. 

 LICENSED PRODUCTS
used by MERIX for its own use in the FIELD, LICENSED PRODUCTS sold to Affiliates, and internal sales for use in service businesses in arms length transactions shall be considered to be NET SALES for purposes of computing royalty obligations, except
such LICENSED PRODUCT used for non-revenue producing activity such as promotional items or field trials shall not be considered to be NET SALES. 
  

	 	j.	“AFFILIATE” shall mean any entity which controls, is controlled by or is under common control with MERIX. An entity shall be regarded as in control of another
entity if it owns or controls more than fifty percent (50%) of the voting power of the entity. 

  

	 	k.	“FOUNDERS” shall mean H. Kim Lyerly, Eli Gilboa, Clay Smith, and Bruce Sullenger, the scientific founders of MERIX, and “FOUNDER” shall mean any of
these individuals. 

  

	 	l.	“EFFECTIVE DATE” shall mean
                                        .

 ARTICLE 2 - LICENSE 
 2.01 - DUKE hereby grants to MERIX and MERIX hereby accepts from DUKE, upon the terms and conditions herein specified, an exclusive worldwide license under the PATENT RIGHTS and KNOW-HOW to make, have
made, use, import, offer to sell, sell, offer to provide and provide LICENSED PRODUCTS. Such license is worldwide to the full end of the term as provided in Article 11.01 hereof, unless sooner terminated as hereinafter provided. DUKE hereby
represents that it has the full right and authority to enter into this AGREEMENT, to grant the licenses provided herein and to perform its other obligations hereunder. 
 2.02 - MERIX shall have the right to grant sub-licenses. Any such sub-licenses shall be subject to terms of this AGREEMENT. Royalties paid to DUKE for NET SALES of LICENSED PRODUCTS by sublicensees shall
be equal to the royalties that would have been paid to DUKE if LICENSED PRODUCTS were sold directly by MERIX. The terms of any non-cash sub-licenses will be negotiated by DUKE and MERIX. MERIX agrees to be responsible for the payment to DUKE of
royalties on funds received by MERIX from its sublicensees and for using commercially reasonable efforts to enforce the terms of the sublicense agreements. If, for any reason, this AGREEMENT is terminated, MERIX agrees to assign all such sublicenses
directly to DUKE. 

  
 - 3 -

 2.03 - It is agreed that, notwithstanding any provisions herein, DUKE is free to use the
             INVENTION and PATENT RIGHTS for its own non-commercial educational, teaching, research and clinical purposes without restriction and without payment of royalties or other fees.

 2.04 - Nothing in this AGREEMENT shall be construed to grant to DUKE any rights in the inventions, discoveries, technology,
patent rights or other intellectual property developed by or for MERIX or its AFFILIATES or sub-licensees and which not covered by the PATENT RIGHTS or KNOW-HOW. 
 2.05 - Within [**] days following the execution of this AGREEMENT and thereafter during the period of this AGREEMENT, DUKE agrees to provide MERIX with copies of all technical know-how it may have or
later obtain relative to the PATENT RIGHTS or KNOW-HOW, and copies of any and all patents or patent applications owned or controlled by DUKE covering the PATENT RIGHTS or KNOW-HOW or the use of the PATENT RIGHTS or KNOW-HOW or processes for the
manufacture of the LICENSED PRODUCTS, including all Patent Office actions received and amendments filed, if any, relative thereto. 
 ARTICLE 3 - ROYALTIES ON NET SALES OF LICENSED PRODUCTS 
 3.01 - As
consideration for the rights granted by DUKE in this AGREEMENT, at the times and in the manner set forth hereinafter, MERIX shall pay to DUKE a royalty on NET SALES of LICENSED PRODUCTS. Such royalty shall be at the rate of
                     percent [    %] of NET SALES of LICENSED PRODUCTS sold by MERIX, by AFFILIATES, or by sublicensees.
[Royalty stacking to be negotiated] 
 3.02 - MERIX will pay to DUKE a minimum annual royalty of
                     dollars ($            ) per year beginning
                                        .

 ARTICLE 4 - MILESTONE BASED ROYALTIES 
 4.01 - As further consideration for the rights granted by DUKE in this AGREEMENT, MERIX shall pay to DUKE milestone based royalties within [**] days of the attainment by MERIX, its AFFILIATES, or its
sublicensees of the commercial milestones specified below. No such milestone payments shall be credited towards other royalties or minimum royalties due. [To Be Negotiated] 

ARTICLE 5 - RECORDS AND REPORTS 
 5.01 - MERIX shall render to DUKE prior to February 28th of each year a written account of progress made toward fulfillment of any due diligence requirements and commercialization of PATENT RIGHTS
pursuant to Article 6. 
 5.02 - MERIX shall render to DUKE prior to February 28th and August 31st of each year a written account of the NET SALES of LICENSED PRODUCTS
subject to royalty hereunder made during the prior six month period ending December 31st and June 30th, respectively, and shall simultaneously pay to DUKE the royalties due on such NET SALES in United States Dollars. Reports tendered shall include the calculation of royalties by LICENSED PRODUCT by
country in substantially the format provided in Appendix A hereto. Minimum annual royalties, if any, which are due DUKE for any calendar year, shall be paid by MERIX along with the written report due on February 28th of each year. 

  
 - 4 -

 5.03 - MERIX will make all payments on or before the date required by the terms of this
AGREEMENT, or within [**] days of any invoice date on invoices received from DUKE. If LICENSEE has not paid any amount due to DUKE in accordance with this Article, DUKE shall increase the amount due (in US Dollars) by an annual percentage rate equal
to [**]%. Such increase(s) shall compound monthly until such time as the LICENSEE has met the full financial obligation due at the time of the next payment or invoice due date. 

5.04 - MERIX shall keep full, true and accurate books of accounts and other records containing all particulars which may be necessary to
properly ascertain and verify the royalties payable by it hereunder. Upon DUKE’s request, MERIX shall permit an independent Certified Public Accountant selected by DUKE (except one to whom MERIX has some reasonable objection) to have access
during ordinary business hours to such of MERIX’s records as may be necessary to determine, in respect of any quarter ending not more than [**] years prior to the date of such request, the correctness of any report and/or payment made under
this AGREEMENT. Such Certified Public Accountant shall execute a written non-disclosure agreement reasonably acceptable to MERIX. 
 5.05 - During the term of this AGREEMENT, representatives of DUKE will meet with representatives of MERIX at times and places mutually agreed upon to discuss the progress and results, as well as ongoing
plans, with respect to the evaluation and development of the PATENT RIGHTS licensed to MERIX; provided, however, that should DUKE’s personnel be required by MERIX to consult with MERIX outside of Durham County, North Carolina, MERIX will
reimburse reasonable travel and living expenses incident thereto. 
 ARTICLE 6 - DUE DILIGENCE REQUIREMENTS 

6.01 - MERIX shall use reasonable commercial diligence in performing research and development to bring LICENSED PRODUCTS to market
through a thorough, vigorous, and diligent program for exploitation of the PATENT RIGHTS, to develop manufacturing capabilities, and to continue active, diligent marketing efforts for LICENSED PRODUCTS throughout the term of this AGREEMENT, and to
vigorously sublicense PATENT RIGHTS for applications MERIX will not pursue throughout the life of this AGREEMENT. 
 6.02 -
[To Be Negotiated] 
 6.03 - DUKE may terminate this AGREEMENT or convert this AGREEMENT to a non-exclusive
AGREEMENT if MERIX fails to meet any of the requirements of this Article and MERIX has failed to cure such failure within [**] days after receiving written notice from DUKE of such failure. 

ARTICLE 7 - PATENTS 
 7.01 - Upon execution of this License Agreement, MERIX will assume the primary responsibility for applying for, seeking prompt issuance of, and maintaining the Patent Rights during the term of the
Agreement. MERIX shall diligently and in a timely manner provide DUKE with copies of all documents relating to the prosecution, maintenance, and validity of the PATENT RIGHTS. MERIX shall consult with DUKE in such prosecution and maintenance, and
shall diligently seek strong and broad claims under the Patent Rights and shall not abandon prosecution of any patent application or any of the claims of the Patent Rights without first notifying DUKE in a timely manner of MERIX’s intention and
reason therefor, and providing DUKE with reasonable opportunity to assume responsibility for prosecution and maintenance of the patents. 

  
 - 5 -

 7.02 - MERIX shall be responsible for and pay all costs and expenses incurred during the
term of this Agreement, for the preparation, filing, prosecution, issuance and maintenance of the Patent Rights. MERIX shall not allow Patent Rights to become abandoned due to nonpayment of fees without first affording DUKE the opportunity to assume
responsibility for further costs and expenses incurred relating to said Patent Rights. 
 7.03 - In the event that DUKE assumes
responsibility for prosecution and maintenance of the Patent Rights pursuant to Section 7.01 or 7.02 above, MERIX shall provide reasonable technical assistance to DUKE in the further prosecution of the Patent Rights. 

7.04 - In the event that this Agreement is terminated pursuant to Article 11 herein, the sole responsibility for applying for, seeking
prompt issuance of, and maintaining the Patent Rights shall revert to the DUKE, and DUKE shall pay expenses subsequently incurred for the preparation, filing, prosecution, issuance and maintenance of the Patent Rights. In the event that
responsibility for patent prosecution reverts to DUKE as specified in this section 7.04, MERIX shall, at its own expense, transfer all pertinent documents and materials related to the PATENT RIGHTS to DUKE in a timely manner. 

ARTICLE 8 - INFRINGEMENT BY THIRD PARTIES 
 8.01 - Upon learning of the infringement of PATENT RIGHTS by a third party, the party learning of such infringement shall promptly inform the other party in writing of that fact along with any evidence
available pertaining to the infringement. MERIX may at its own expense take whatever steps are necessary to stop the infringement and recover damages. In such case, MERIX will keep DUKE informed of the steps taken and the progress of any legal
actions taken. MERIX will pay to DUKE royalties pursuant to Article 3.01 on any such damages recovered as consideration for lost sales of LICENSED PRODUCTS that are in excess of legal expenses incurred by MERIX in enforcing its PATENT RIGHTS. If
MERIX does not undertake, within [**] days of notice, to enforce the PATENT RIGHTS against the infringing party, DUKE shall have the right, at its own expense to take whatever steps are necessary to stop the infringement and recover damages, and
shall be entitled to retain damages so recovered (after reimbursing MERIX for any of its expenses in cooperating with DUKE in prosecuting such infringement). 
 ARTICLE 9 - GOVERNMENT CLEARANCE AND EXPORT 
 9.01 - LICENSEE agrees to use
its best efforts to have the LICENSED PRODUCTS cleared for marketing and sale in those countries in which LICENSEE intends to sell LICENSED PRODUCTS by the responsible government agencies requiring such clearance. Where such clearance requires
payment of taxes or fees, LICENSEE shall maintain full responsibility for that payment, which shall not be creditable against any other amounts due under this AGREEMENT. To accomplish said clearances at the earliest possible date, MERIX agrees to
file, according to the usual practice of MERIX, any necessary data with said government agencies. 

  
 - 6 -

 9.02 - This AGREEMENT is subject to all of the United States laws and regulations
controlling the export of technical data, computer software, laboratory prototypes and other commodities and technology. 

ARTICLE 10 - PUBLICATION 
 10.01 - MERIX agrees that the right of publication of the              INVENTION and information in related PATENT RIGHTS shall reside in the
inventors and other staff of DUKE. DUKE shall use reasonable efforts to provide MERIX a review copy of such publications [**] days in advance of submission for publication or public disclosure, but such prior review by MERIX will be in no way
construed as a right to restrict such publication. Such review shall be granted solely so that DUKE and MERIX can perfect patent protection prior to public disclosure. MERIX shall also have the right to publish and/or co-author any publication on
the              INVENTION based upon data developed by MERIX. 

ARTICLE 11 - DURATION AND TERMINATION 
 11.01 - This AGREEMENT shall become effective upon the EFFECTIVE DATE, and unless sooner terminated in accordance with any of the provisions herein, shall remain in full force and effect for the longer
of: (i) the life of the last-to-expire of the patents included in the PATENT RIGHTS or any patents issued on KNOW-HOW; or (ii)              (    ) years from
the EFFECTIVE DATE hereof. Upon the expiration of this AGREEMENT, DUKE shall grant MERIX an exclusive, worldwide, fully paid license, with the right to grant sub-licenses, under KNOW-HOW to make, have made, use, import, offer to sell, sell, offer to
provide and provide LICENSED PRODUCTS. 
 11.02 - MERIX may terminate this AGREEMENT by giving DUKE written notice at least
three (3) months prior to such termination, and thereupon terminate the manufacture, use or sale of LICENSED PRODUCTS. 

11.03 - Either party may immediately terminate this AGREEMENT for fraud, willful misconduct, or illegal conduct of the other party that
materially adversely affects such party upon written notice of same to that other party. Except as provided above, if either party fails to fulfill any of its material obligations under this AGREEMENT, the non-breaching party may terminate this
AGREEMENT, upon written notice to the breaching party, as provided below. Such notice must contain a full description of the event or occurrence constituting a breach of this AGREEMENT. The party receiving notice of the breach shall submit a plan to
cure such breach to the non-defaulting party within [**] days of receipt of such notice. The plan shall be subject to the reasonable acceptance, rejection or modification by the non-defaulting party within [**] days of receipt of the plan. The
defaulting party shall have the opportunity to cure that breach in accordance with the terms of the accepted plan. If the breach is not cured within that time, the termination will be effective as of the end of the cure period set forth in the
accepted plan. A party’s ability to cure a breach will apply only to the first two breaches properly noticed under the terms of this AGREEMENT, regardless of the nature of those breaches. Any subsequent breach by that party will entitle the
other party to terminate this AGREEMENT upon proper notice. 

  
 - 7 -

 11.04 - Upon the termination of this AGREEMENT, MERIX may notify DUKE of the amount of
LICENSED PRODUCTS MERIX then has on hand and MERIX shall then have a license to sell that amount of LICENSED PRODUCTS, but no more, provided MERIX shall pay the royalty thereon at the rate and at the time provided for herein. 

11.05 - If during the term of this Agreement, MERIX shall become bankrupt or insolvent or if the business of MERIX shall be placed in the
hands of a receiver or trustee, whether by the voluntary act of MERIX or otherwise, or if MERIX shall cease to exist as an active business, this Agreement shall immediately terminate as though with MERIX breach, and DUKE shall have all the remedies
and rights available to it for termination with cause; provided, however, that this provision shall not apply to a reorganization of MERIX under Chapter 11 of the United States Bankruptcy Code. 

ARTICLE 12 - LAW TO GOVERN 
 12.01 - This AGREEMENT shall be construed and enforced in accordance with the laws of the State of North Carolina. 
 ARTICLE 13 - NOTICES 
 13.01 - Notice hereunder shall be deemed sufficient
if personally delivered, if given by registered mail, postage prepaid, or by national overnight courier, charges prepaid, and in each instance addressed to the party to receive such notice at the address given below, or such other address as may
hereafter be designated by notice in writing. 
  

			
	DUKE	 	MERIX
		
	 Office of Science and Technology

Duke University
 Room 230, North
Building
 Box 90083
 Durham, NC
27708
	 	 P.O. Box 14509
 Research
Triangle Park, NC 27709
 ATTENTION: CEO

		
	 cc: Office of the University Counsel
 Duke University Medical Center
 DUMC Box 3024

2400 Pratt Street, Suite 4000
 Durham NC
27710
	 	 cc: Fred D. Hutchison, Esquire

Hutchison & Mason PLLC
 4011 Westchase
Blvd.
 Suite 400
 Raleigh NC
27607

  
 - 8 -

 13.02 - Information and transactions exchanged between the parties in relation to financial
consideration contemplated under this AGREEMENT, including but not limited to royalty reports and payments, shall be tendered to the following offices of each party respectively: 

 

			
	DUKE	 	MERIX
		
	 Office of Science and Technology

Duke University
 Room 230, North
Building
 Box 90083
 Durham, NC
27708
	 	 P.O. Box 14509
 Research
Triangle Park, NC 27709
 ATTENTION: CEO

		
	 cc: Office of the University Counsel
 Duke University Medical Center
 DUMC Box 3024

2400 Pratt Street, Suite 4000
 Durham NC
27710
	 	 cc: Fred D. Hutchison, Esquire

Hutchison & Mason PLLC
 4011 Westchase
Blvd.
 Suite 400
 Raleigh NC
27607

 ARTICLE 14 - ASSIGNMENT 
 14.01 - This AGREEMENT shall be binding upon and inure to the benefit of the respective successors and assigns of the parties hereto. However, MERIX may not assign its rights in this AGREEMENT without
approval by DUKE, such approval not to be unreasonably withheld; provided, however, that no such approval shall be required from DUKE if this AGREEMENT is assigned in connection with the sale of all or substantially all of the assets or stock of
MERIX, whether by merger, acquisition or otherwise. 
 ARTICLE 15 - INDEMNITY, INSURANCE, REPRESENTATIONS, STATUS

 15.01 - MERIX agrees to indemnify, hold harmless and defend DUKE, its officers, employees, and agents, against any and
all claims, suits, losses, damages, costs, fees, and expenses asserted by third parties, both government and non-government, resulting from or arising out of the exercise of the license granted under this AGREEMENT. MERIX shall not be responsible
for the negligence or intentional wrong doing of DUKE. 
 15.02 - MERIX shall maintain in force at its sole cost and expense,
with reputable insurance companies, general liability insurance and products liability insurance coverage in amounts customary for companies similarly situated in the same industry. DUKE shall have the right to ascertain from time to time that such
coverage exists, such right to be exercised in a reasonable manner. In lieu of said coverage, DUKE agrees to consider the existence of an adequate self-insurance program as an acceptable alternative. 

15.03 - NOTHING IN THIS AGREEMENT SHALL BE DEEMED TO BE A REPRESENTATION OR WARRANTY BY DUKE OF THE VALIDITY OF ANY OF THE PATENTS OR THE
ACCURACY, SAFETY, EFFICACY, OR USEFULNESS, FOR ANY PURPOSE, OF ANY PATENT RIGHTS. DUKE SHALL HAVE NO OBLIGATION, EXPRESS OR IMPLIED, TO SUPERVISE, MONITOR, REVIEW OR OTHERWISE ASSUME RESPONSIBILITY FOR THE PRODUCTION, MANUFACTURE, TESTING, MARKETING
OR SALE OF ANY LICENSED PRODUCT, AND DUKE SHALL HAVE NO LIABILITY WHATSOEVER TO MERIX OR ANY THIRD PARTIES FOR OR ON ACCOUNT OF ANY INJURY, LOSS, OR DAMAGE, OF ANY KIND OR NATURE, SUSTAINED BY, OR ANY DAMAGE ASSESSED OR ASSERTED AGAINST, OR ANY
OTHER LIABILITY INCURRED BY OR IMPOSED UPON MERIX OR ANY OTHER PERSON OR ENTITY, ARISING OUT OF OR IN CONNECTION WITH OR RESULTING FROM: 
  

	 	a.	the production, use, or sale of any LICENSED PRODUCT; 

  
 - 9 -

	 	b.	the use of any PATENT RIGHTS by MERIX or its sublicensees; or 

  

	 	c.	any advertising or other promotional activities by MERIX with respect to any of the foregoing. 

15.04 - Neither party hereto is an agent of the other party for any purpose whatsoever. 

ARTICLE 16 - USE OF A PARTY’S NAME 
 16.01 - Neither party will, without the prior written consent of the other party: 
  

	 	a.	use in advertising, publicity or otherwise, any trade-name, personal name, trademark, trade device, service mark, symbol, or any abbreviation, contraction or simulation
thereof owned by the other party; or 

  

	 	b.	represent, either directly or indirectly, that any product or service of the other party is a product or service of the representing party or that it is made in
accordance with or utilizes the information or documents of the other party. 

 ARTICLE 17 - SEVERANCE, WAIVER
AND ALTERATION 
 17.01 - Each clause of this AGREEMENT is a distinct and severable clause and if any clause is deemed
illegal, void or unenforceable, the validity, legality or enforceability of any other clause or portion of this AGREEMENT will not be affected thereby. 
 17.02 - The failure of a party in any instance to insist upon the strict performance of the terms of this AGREEMENT will not be construed to be a waiver or relinquishment of any of the terms of this
AGREEMENT, either at the time of the party’s failure to insist upon strict performance or at any time in the future, and such terms will continue in full force and effect. 

17.03 - Any alteration, modification, or amendment to this AGREEMENT must be in writing and signed by both parties. 

ARTICLE 18 - CONFIDENTIALITY 
 18.01 - During the term of this AGREEMENT and for a period of [**] years following the expiration of termination of this AGREEMENT, DUKE and MERIX each agree to treat any confidential information
disclosed to it by the other party to this AGREEMENT with reasonable care and to avoid disclosure of such information to any other person, firm or corporation, except AFFILIATES, and either party shall be liable for unauthorized disclosure or
failure to exercise such reasonable care. Neither party shall have an obligation, with respect to confidential information disclosed to it, or any part thereof, which: 
  

	 	(a)	is already known to the party at the time of the disclosure; 

  
 - 10 -

	 	(b)	becomes publicly known without the wrongful act or breach of this AGREEMENT by the party; 

 

	 	(c)	is rightfully received by the party from a third party on a non-confidential basis; 

 

	 	(d)	is subsequently and independently developed by employees of the party who had no knowledge of the information, as verified by written records; or

  

	 	(e)	is approved for release by written authorization of the party disclosing the information. 

18.02 - DUKE and MERIX agree that any information to be treated as confidential information under this Article 18 must be disclosed in
writing or in another tangible medium and must be clearly marked “CONFIDENTIAL”. Information disclosed orally must be summarized and reduced to writing and communicated to the other party within [**] days, and the other party agrees that
such disclosed information shall be deemed confidential. 
 18.03 - Notwithstanding the foregoing, MERIX shall have the right to
use and disclose any Confidential Information related to the PATENT RIGHTS and KNOW-HOW to investors, prospective investors, employees and agents with a need to know, collaborators, prospective collaborators and other third parties in the chain of
manufacturing and distribution provided that MERIX obtains from such parties written confidentiality agreements the provisions of which are at least as strenuous as those provided in this Article 18. If a party refuses to execute a written
confidentiality agreement, MERIX may request from DUKE that such requirement be waived, such consent to waiver not to be unreasonably withheld by DUKE. 
 ARTICLE 19 - TRANSFER OF MATERIALS 
 19.01 - Any transfer of materials
between DUKE and MERIX in connection with this AGREEMENT shall be made under the terms of the Master Materials Transfer Agreement [MMTA], said MMTA being incorporated in its entirety as Appendix B of the present AGREEMENT. 

ARTICLE 20 - TITLES 
 20.01 - All titles and article headings contained in this AGREEMENT are inserted only as a matter of convenience and reference. They do not define, limit, extend or describe the scope of this AGREEMENT or
the intent of any of its provisions. 

  
 - 11 -

 ARTICLE 21 - ENTIRE UNDERSTANDING 

21.01 - This AGREEMENT represents the entire understanding between the parties with respect to the subject matter hereof, and supersedes
all other agreements, express or implied, between the parties concerning the              INVENTION, and PATENT RIGHTS. 

  
 - 12 -

 IN WITNESS WHEREOF, the parties have caused these presents to be executed in
duplicate as of the date and year first above written. 
  

					
	SEAL	 	DUKE UNIVERSITY
			
		 	By:	 	  

		 		 	Robert Taber
		 		 	Director, Office of Science & Technology
			
		 	Date:	 	  

		
	SEAL	 	MERIX BIOSCIENCE, INC.
			
		 	By:	 	  

			
		 	Title:	 	  

			
		 	Date:	 	  

  
 - 13 -

 Appendix A 
 License Agreement for 1101 INVENTION and 1215 INVENTION 
 ROYALTY REPORT
for period ending              
 Duke File # 

 

																									
	 Country
	 	Product	 	Sales in
<Month>	 	Sales in
<Month>	 	Sales in
<Month>	 	Sales in
<Month>	 	Sales in
<Month>	 	Sales in
<Month>	 	TOTAL
GROSS
SALES1	 	Reductions
to Sales2	 	TOTAL
NET
SALES	 	%
Royalty
Due3	 	TOTAL
ROYALTY
DUE
													
	 SubTOTAL x Country
	 		 		 		 		 		 		 		 		 		 		 		 	
													
	 SubTOTAL x Country
	 		 		 		 		 		 		 		 		 		 		 		 	
													
	 GRAND TOTAL
	 		 		 		 		 		 		 		 		 		 		 		 	
												
		 		 		 		 		 		 	 Royalty Credits Taken
	 		 		 		 		 	
												
		 		 		 		 		 		 	 TOTAL Royalty Credits
	 		 		 		 		 	
													
	 ROYALTIES PAID
	 		 		 		 		 		 		 		 		 		 		 		 	

  

	1 	 Includes sales by Affiliates or by sublicensees of Merix. 

	2 	 Note that Reductions to Sales are limited by the definition of Net Sales as set forth in Section 1.01(f) of Article 1 of the License Agreement

	3 	 The Percentage of Royalty Due shall be decreased in accordance with Section 4.03 of Article 4 of the License Agreement

  
 - 1 -

 APPENDIX B: MASTER MATERIALS TRANSFER AGREEMENT 

MASTER MATERIAL TRANSFER AGREEMENT 
 between 
 DUKE UNIVERSITY 

Durham, NC 27710 

(“DUKE”) 

and 

MERIX BIOSCIENCE, INC. 
 Durham, NC 
 (“MERIX”) 

Pursuant to the License Agreement between the parties dated 10 January 2000 for the inventions described in the Duke University
Office of Technology file # 1101 and 1215 (the “LICENSE AGREEMENT”) and subject to the terms of the LICENSE AGREEMENT, this Master Material Transfer Agreement (“Agreement”) defines the terms by which either party hereto shall
have the right to request reasonable amounts of research materials from the other party which are reasonable, necessary, and useful to the purposes of the LICENSE AGREEMENT (“Original Materials”), such requests not to be unreasonably
denied. Hereinafter, the party providing its Original Materials shall be referred to as the “PROVIDING PARTY” and the party receiving the other party’s Original Materials shall be referred to as the “RECEIVING PARTY”. It is
understood and agreed that “PROVIDING PARTY” and “RECEIVING PARTY” shall include the Affiliates of MERIX or DUKE as defined below. 
 For the purposes of this Agreement, the following definitions shall be recognized by both parties: 
 Progeny: Unmodified descendant from the Original Materials, such as virus from virus, cell from cell, or organism from organism. 

Unmodified Derivatives: Substances created by the RECEIVING PARTY which constitute an important unmodified
functional sub-unit or expression product of the Original Materials, e.g., subclones of unmodified cell lines, purified or fractionated sub-sets of the Original Materials such as novel plasmids or vectors, proteins expressed by DNA or RNA, or
antibodies secreted by a hybridoma. 
 Material: Original Material plus Progeny and Unmodified
Derivatives or any related biological material or associated know-how and data received by Receiving Party from Providing Party. Material shall not include any Modifications (as defined below). 

Modifications: Substances created by the RECEIVING PARTY which contain/incorporate any form of the Material
(Original Materials, Progeny or Unmodified Derivatives). 

  
 - 1 -

 Affiliates: Any corporation or non-corporate entity which controls,
is controlled by, or is under common control with a party hereto. A corporation or non-corporate entity, as applicable, shall be regarded as in control of another corporation if it owns or directly or indirectly controls at least fifty percent
(50%) of the voting stock of the other corporation or if it possess, directly or indirectly, the power to direct or cause the direction of the management and policies of such corporation or non-corporate entity, as applicable. 

Materials are to be provided under the following terms and conditions: 
  

	1)	Exchange of Original Materials shall be documented through the use of Material Transfer Record forms, samples of which are appended hereto as Exhibits I and II.
Materials are and shall remain the property of the PROVIDING PARTY. Subject to Section 8 of this Agreement, Materials shall be used by the RECEIVING PARTY solely for research and development purposes, including those purposes permitted in the
LICENSE AGREEMENT. The Materials shall be used at RECEIVING PARTY’s facilities only unless prior written consent to the transfer of the Materials has been obtained from the Providing Party. RECEIVING PARTY agrees not to transfer the Materials
or Modifications to anyone who does not work under its direct supervision at RECEIVING PARTY’s facilities without the prior written consent of PROVIDING PARTY. RECEIVING PARTY agrees to protect Confidential Information supplied by PROVIDING
PARTY regarding Materials in accordance with the confidentiality provisions set forth in the LICENSE AGREEMENT. 

  

	2)	PROVIDING PARTY does not claim ownership of substances and Modifications produced as a result of RECEIVING PARTY’s research with materials that are not included in
the definition of Materials above. Notwithstanding the foregoing and subject to Section 5 hereof, PROVIDING PARTY retains ownership of any form of the Materials contained in a Modification. 

 

	3)	DUKE shall be free to use the results of its research with the Materials for its own teaching, research, educational, clinical and publication purposes without the
payment of royalties or other fees to MERIX. Confidential Information shall be governed by the confidentiality provisions contained in the LICENSE AGREEMENT. Should RECEIVING PARTY wish to publish the results of its research from the Materials
provided by PROVIDING PARTY, RECEIVING PARTY shall submit in writing to PROVIDING PARTY, for its review and comment, a copy of any proposed publication resulting from the subject research with the Materials at least [**] days prior to the estimated
date of publication, and if no response is received from PROVIDING PARTY within [**] days of the date submitted to PROVIDING PARTY, it will be conclusively presumed that the publication may proceed without delay. RECEIVING PARTY shall acknowledge
PROVIDING PARTY as the source of the Materials in all publications containing any data or information about the Materials, unless PROVIDING PARTY indicated otherwise and subject to the confidentiality provisions set forth in the LICENSE AGREEMENT.
If PROVIDING PARTY determines that the proposed publication contains patentable subject matter or the disclosure of Confidential Information which requires protection, PROVIDING PARTY may require the delay of the publication for a period of time not
to exceed [**] days for the purpose of allowing the pursuit of such patent protection or the deletion of Confidential Information. In the case of joint publications, authorship shall be determined by normal academic standards, taking into account
the role and contribution of each investigator. 

  
 - 2 -

	4)	RECEIVING PARTY will inform PROVIDING PARTY, in confidence, of research results related to the Material by personal written communication or by providing PROVIDING
PARTY with a draft manuscript describing the results of such research. PROVIDING PARTY shall accept and maintain such results in confidence until published. 

 

	5)	Except as expressly provided in this Agreement or the LICENSE AGREEMENT, transfer of Materials conveys no rights to RECEIVING PARTY under any patent applications,
patents, trade secrets or other proprietary rights of PROVIDING PARTY except as provided in the LICENSE AGREEMENT. In particular, no rights are provided to RECEIVING PARTY for use of the Materials or Modifications for profit-making or commercial
purposes except as provided in the LICENSE AGREEMENT. If RECEIVING PARTY desires to use the Materials or Modifications for such commercial purposes, RECEIVING PARTY agrees that it must first negotiate a license or other appropriate agreement with
PROVIDING PARTY and third parties as may be required. However, to the extent that PROVIDING PARTY can legally do so, RECEIVING PARTY is hereby granted a non-exclusive, royalty-free license to use Material included in Modifications for RECEIVING
PARTY’s own internal noncommercial research purposes. RECEIVING PARTY shall not use PROVIDING PARTY’s Materials or Modifications in research that is subject to consulting or licensing obligations to a third party, unless prior written
permission is obtained from PROVIDING PARTY. PROVIDING PARTY shall be free, in its sole discretion, to distribute its Materials to others and to use its Materials for its own purposes to the full extent it may legally do so.

  

	6)	If RECEIVING PARTY’S research results in a discovery, an invention, a new use or a product (collectively referred to as “Materials Discovery”), based on,
containing, or relating to the Materials or Modifications received from PROVIDING PARTY, RECEIVING PARTY shall promptly and confidentially disclose the Materials Discovery to the PROVIDING PARTY as well as the role, if any, of RECEIVING PARTY, its
employees’ and/or agents in the creation of the Materials Discovery. Inventorship of any Materials Discovery shall be determined by patent law or by mutual agreement if the Materials Discovery is not patentable. Title to Materials Discoveries
shall reside with MERIX if MERIX personnel are the sole inventors, with DUKE if DUKE personnel are the sole inventors, and will be held jointly if both DUKE and MERIX personnel are inventors. To the extent that DUKE owns the rights of sole or joint
inventorship of any Materials Discovery, MERIX is hereby granted an option to acquire an exclusive, worldwide, royalty-bearing license as set forth in the LICENSE AGREEMENT. Notwithstanding the above, PROVIDING PARTY or joint owner of any Materials
Discovery shall be free to use any Materials Discovery for its own internal research purposes without the payment of royalties or other fees. 

  
 - 3 -

	7)	Any Materials delivered pursuant to this Agreement are understood to be experimental in nature, and PROVIDING PARTY MAKES NO REPRESENTATIONS AND EXTENDS NO WARRANTIES
OF ANY KIND, EITHER EXPRESS OR IMPLIED. THERE ARE NO EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR THAT THE USE OF THE MATERIALS OR MODIFCATIONS THEREOF WILL NOT INFRINGE ANY PATENT, COPYRIGHT, TRADEMARK OR
OTHER PROPRIETARY RIGHTS. 

  

	8)	In no event shall PROVIDING PARTY be liable for any use by RECEIVING PARTY, its employees and/or agents of Materials or for any loss, claim, damage, or liability, of
any kind or nature, that may arise from or in connection with RECEIVING PARTY’s use, handling, storage, or disposal of the Materials or Modifications, except as such claims, demands, costs or judgment arise from PROVIDING PARTY’s
negligence or willful misconduct. Except to the extent prohibited by law, RECEIVING PARTY assumes responsibility for, and agrees to indemnify and hold harmless PROVIDING PARTY and PROVIDING PARTY’s trustees, directors, officers, agents, and
employees from and against any liability, loss or damage they may suffer as a result of any claims, demand, costs or judgments against them arising out of RECEIVING PARTY’s use, handling, storage or disposal of the Materials or Modifications,
except as such claims, demands, costs, or judgments may also arise from the indemnified party’s negligence or willful misconduct or from PROVIDING PARTY’s publication or distribution of any reports, data or other information relating to
said Material. 

  

	9)	Materials or Modification shall in no event be used in human beings (including for diagnostic purposes), and all research involving the Materials or Modifications
(including but not limited to research involving the use of animals and recombinant DNA) shall be conducted in accordance with all federal, state, local and other laws, regulations, and ordinances governing such research, including applicable NIH
guidelines, if used in the United States. 

  

	10)	This Agreement will become effective when signed by both parties and shall terminate upon the termination or expiration of the LICENSE AGREEMENT, unless extended by
written mutual agreement between MERIX and DUKE. Upon termination of this Agreement, RECEIVING PARTY will at the direction of PROVIDING PARTY immediately discontinue its use of PROVIDING PARTY’s Materials and will, upon direction of PROVIDING
PARTY, return or destroy such Materials promptly upon notice. RECEIVING PARTY will have the option of either destroying Materials and/or Modifications of PROVIDING PARTY’s Materials or remain bound by the terms of this Agreement as they apply
to such Materials and/or Modifications, as the case may be. Paragraphs 2, 3, 4, 5, 6, 7, 8, 10 and 11 shall survive termination of this Agreement. 

  

	11)	Neither party shall use the name of the other party in any advertising, publicity or otherwise without the written consent of the other party. 

  
 - 4 -

	12)	Neither party may assign this Agreement without the prior written consent of the other party; provided, however, that no such consent shall be required in connection
with the sale of all of substantially all the assets or capital stock of a party, whether by merger, sale of stock or assets or otherwise. This Agreement shall be governed by the laws of the State of North Carolina, without reference to its choice
of law provisions. The parties hereby submit to the jurisdiction of the courts of North Carolina in all matters concerning this Agreement. 

 AGREED: 
  

											
	DUKE:	 	MERIX:	 	
			
	Duke University	 	Merix Bioscience Inc.	 	
						
	By:	 	  
	 		 	By:	 	  
	 	
	Andrew E. Balber, Ph.D.	 		 	Name:	 	  
	 	
	Associate Director	 		 	Title:	 	  
	 	
	Office of Science & Technology	 		 		 		 	
			
	Date executed:                      	 	Date executed:                      	 	

  

  
 - 5 -

 EXHIBIT I 
 MATERIAL TRANSFER RECORD 
 Duke University 

Durham, NC 27710 

(“PROVIDING PARTY”) 
 to 
 MERIX BIOSCIENCE, Inc. 

Durham, NC 

(“RECEIVING PARTY”) 

The Original Materials described below are supplied by PROVIDING PARTY to RECEIVING PARTY subject to the terms and conditions of the LICENSE AGREEMENT
between Duke University and MERIX, Inc. dated 10 January 2000 for the inventions described in the Duke University Office of Technology Transfer file # 1101 and 1215 (the “LICENSE AGREEMENT”) and the Master Materials Transfer Agreement
dated                      between such parties. Duplicate originals of this form shall be executed and one fully executed form shall be given to the
Principal Investigator of PROVIDING PARTY and one to the Principal Investigator of RECEIVING PARTY. 
  

					
	Description of Original Materials:	 	  
	 	
	
	  

	
	  

 In signing below, PROVIDING PARTY’s Principal Investigator and the RECEIVING PARTY’s Principal Investigator
acknowledge that they understand and will abide by the terms and conditions of the LICENSE AGREEMENT and Master Materials Transfer Agreement pursuant to which the Original Materials are provided. 

AGREED: 
  

					
	PROVIDING PARTY	 		 	RECEIVING PARTY
			
	  
	 		 	  

	Principal Investigator	 		 	Principal Investigator
			
	  
	 		 	  

	Date Material(s) sent	 		 	Date Material(s) received

  
 - 6 -

 EXHIBIT II 
 MATERIAL TRANSFER RECORD 
 MERIX BIOSCIENCE, Inc. 

Durham, NC 

(“PROVIDING PARTY”) 
 to 
 Duke University 

Durham, NC 27710 

(“RECEIVING PARTY”) 

The Original Materials described below are supplied by PROVIDING PARTY to RECEIVING PARTY subject to the terms and conditions of the License Agreement
between Duke University and MERIX BIOSCIENCE, Inc. dated 10 January 2000 for the inventions described in the Duke University Office of Technology Transfer file # 1101 and 1215 (the “LICENSE AGREEMENT”) and the Master Materials
Transfer Agreement dated                      between such parties. Duplicate originals of this form shall be executed and one fully executed form
shall be given to the Principal Investigator of PROVIDING PARTY and one to the Principal Investigator of RECEIVING PARTY. 
  

					
	Description of Original Materials:	 	  
	 	
	
	  

	
	  

 In signing below, PROVIDING PARTY’S Principal Investigator and RECEIVING PARTY’S Principal Investigator
acknowledge that they understand and will abide by the terms and conditions of the LICENSE AGREEMENT and Master Materials Transfer Agreement pursuant to which the Original Materials are provided. 

AGREED: 
  

					
	PROVIDING PARTY	 		 	RECEIVING PARTY
			
	  
	 		 	  

	Principal Investigator	 		 	Principal Investigator
			
	  
	 		 	  

	Date Material(s) sent	 		 	Date Material(s) received

  
 - 7 -

 FIRST AMENDMENT TO 

EXCLUSIVE LICENSE AGREEMENT 
 THIS FIRST AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT (the “First Amendment”) is made and dated as of July 28, 2003, by and between MERIX Bioscience, Inc., a Delaware corporation with
its principal place of business at 4233 Technology Drive, Durham, NC 27704 (“MERIX”), and Duke University, a North Carolina not-for-profit corporation having its Office of Science and Technology offices located at the Grey Building,
2020 E. Main Street, Durham, NC 27705 (“DUKE”). 
 WHEREAS, MERIX and DUKE are parties to that certain
Exclusive License Agreement dated January 10, 2000 whereby MERIX obtained certain rights in and to patents and know-how described in DUKE’s Office of Science and Technology files #1215 (the “License Agreement”); and

 WHEREAS, the parties hereto desire to modify the terms of the License Agreement. 

NOW, THEREFORE, in consideration of the mutual agreements contained herein, the adequacy and sufficiency of which are hereby
acknowledged, the parties hereto agree as follows: 
 1. Defined Terms. Terms that are used herein with initial capital
letters and that are not otherwise defined shall have the meanings given to them in the License Agreement. 
 2. Article
2.02. Article 2.02 of the License Agreement is hereby amended by appending the following clause to the end of such article: 
 “, and DUKE agrees that all such sublicenses assigned to DUKE shall survive the termination or expiration of this AGREEMENT. DUKE further agrees that any sublicensee of MERIX shall have the right to
further sublicense the PATENT RIGHTS, subject to the terms of this AGREEMENT” 
 3. Article 7.04. The following new
Article 7.04 is incorporated into the License Agreement: 
 “7.04—MERIX shall have the right to
delegate some portion of its obligations under this Article 7 to its sublicensees, subject to providing timely notice to DUKE of its intention to do so and further subject to such sublicensee agreeing to assume such obligations. In the event that
this AGREEMENT is terminated, such rights and obligations previously assumed by such sublicensees shall survive.” 
 4.
Article 7.05. Exisitng Article 7.04 is re-numbered as Article 7.05, the reference in the article to section 7.04 is amended to be 7.05, and the following language is inserted at the beginning of the first sentence of the article: 

“Except as otherwise set forth in Section 7.04,” 

5. Article 8.01. Article 8.01 of the License Agreement is hereby amended by inserting the following language following the first
complete sentence of the article: 

 “MERIX shall have the first right to enforce any of the PATENT RIGHTS
against any third party against any infringement or alleged infringement thereof.” 
 6. Article 8.01. Article 8.01
of the License Agreement is hereby further amended by inserting the following language following the third complete sentence of the article: 
 “MERIX shall have the right, as reasonably required, to name DUKE as a necessary party, or to bring suit in DUKE’s name, in any legal actions taken by MERIX hereunder but only to protect
MERIX’ interest in the licensed technology.” 
 7. Article 8.02. The following new Article 8.02 is incorporated
into the License Agreement: 
 “8.02—MERIX shall have the right to delegate its obligations with
respect to some portion of the PATENT RIGHTS under this Article 8 to its sublicensees, subject to providing timely notice to DUKE of its intention to do so and further subject to such sublicensee agreeing to assume such obligations. In the event
that this AGREEMENT is terminated, such rights and obligations previously assumed by such sublicensees shall survive.” 

8. Effect of First Amendment. The provisions of the License Agreement are amended and modified by the provisions of this First
Amendment. If any provisions of the License Agreement are materially different from or inconsistent with any of the provisions of this First Amendment, the provisions of this First Amendment shall control, and the provisions of the License Agreement
shall, to the extent of such difference or inconsistency, be deemed to be amended and modified. 
 9. Single Agreement.
This First Amendment and the License Agreement, as amended and modified by the provisions of this First Amendment, shall constitute and be construed as a single agreement. 
 10. Governing Law. This First Amendment shall be governed by and construed in accordance with the laws of the State of North Carolina. 

IN WITNESS WHEREOF, the parties hereto have duly executed this First Amendment as of the date first written above. 

 

			
	DUKE UNIVERSITY
		
	 By:
	 	/s/ Robert L. Taber
		 	 
		 	 Robert L. Taber, Ph.D.

Vice Chancellor and Director
 Office of Science
& Technology

		 	
	
	MERIX BIOSCIENCE, INC.
		 	
	By:	 	/s/ Timothy W. Trost
		 	 
		 	 Name:  Timothy W. Trost

Title:    Vice President & CFOExclusive License Agreement, dated as of January 15, 2002

 Exhibit 10.18 
 Confidential Materials omitted and filed separately with the 
 Securities and
Exchange Commission. Asterisks denote omissions. 
 EXCLUSIVE LICENSE AGREEMENT - TREATING AUTOIMMUNE DISEASES 

This Exclusive License Agreement (this “Agreement”) is made on January 15th, 2002, by and between BAYLOR RESEARCH INSTITUTE
(“Institute”), a nonprofit corporation organized and existing under the laws of the State of Texas, having its principal office at 3434 Live Oak, Dallas, Texas, 75204 (“Institute”), and MERIX Bioscience, Inc., a Delaware
corporation (“Licensee”), with its principal offices at 4233 Technology Drive, Durham, North Carolina 27704. This Agreement is effective as of the date hereof (the “Effective Date”). 

BACKGROUND 
  

	A.	Institute is the owner by assignment from the inventors of certain intellectual property developed by Dr. Jacques Banchereau, Anna Karolina Palucka, and Patrick
Blanco, currently or previously at Institute relating to treating autoimmune diseases (as described more fully in Attachment 1, the “Intellectual Property”); 

 

	B.	Institute has the right to grant licenses under said Intellectual Property; 

 

	C.	Licensee desires to obtain an exclusive worldwide right and license to use and exploit the Intellectual Property; and 

 

	D.	Institute has determined that the exploitation of the Intellectual Property is in the best interest of Institute and is consistent with its educational and research
missions and goals. 

 NOW, THEREFORE, in consideration of the promises and covenants contained in this Agreement
and intending to be legally bound, the parties agree as follows: 
 ARTICLE 1 

DEFINITIONS 
 1.1. “Affiliate” means any legal entity directly or indirectly controlling, controlled by or under common control with Licensee that has executed (a) this Agreement or (b) a written
joinder agreement, in a form reasonably satisfactory to Institute, agreeing to be bound by all of the terms and conditions of this Agreement as if such Affiliate were an original party to this Agreement. For purposes of this Agreement,
“control” means the direct or indirect ownership of more than fifty percent (50%) of the outstanding voting securities of a legal entity, or the right to receive more than fifty percent (50%) of the profits or earnings of a legal
entity, or the right to control the policy decisions of a legal entity. 
 1.2. “Agreement” shall have the meaning
given in the first paragraph hereof. 

  
 -1-

 1.3. “Calendar Half” means each six-month period, or any portion thereof,
beginning on January 1 and July 1. 
 1.4. “Common Stock” shall have the meaning given in
Section 3.1.2. 
 1.5. “Confidential Information” means and includes all technical information, inventions,
developments, discoveries, software, know-how, methods, techniques, formulae, data, processes and other proprietary ideas, whether or not patentable or copyrightable, regardless whether Institute identifies such information as confidential or
proprietary at the time it is delivered or communicated to Licensee. 
 1.6. “Default” shall have the meaning given in
Section 5.3 
 1.7. “Effective Date” shall have the meaning given in the preamble hereof. 

1.8. “Fair Market Value” means the cash consideration that Licensee or its Sublicensee would realize from an unaffiliated,
unrelated buyer in an arm’s length sale of an identical item sold in the same quantity and at the same time and place of the transaction. 
 1.9. “Improvement,” means any modification of a discovery (which discovery has been disclosed in the U.S. patent application for Institute Patent Rights), whether or not patentable, made by Dr,
[**] and/or his colleagues, reduced to practice during the term of research sponsored by Licensee under the Research Support and Option Agreement, between the parties and dated August 30, 2001 and in the Field of Use. 

1.10 “Indemnified Party” shall have the meaning given in Section 8.2. 

1.11. “Field of Use” means research and development, diagnosis, prevention, therapy and monitoring of autoimmune
diseases. 
 1.12. “Liability” and “Liabilities” shall have the meaning given in Section 8.2.

 1.13. “License” shall mean the license granted by Institute to Licensee pursuant to Section 2.1. 

1.14. “Licensee” shall have the meaning given in the first paragraph of this Agreement. 

1.15. “Net Sales” means the consideration or Fair Market Value attributable to the Sale of any Institute Licensed Product(s),
less (if initially included in the consideration) qualifying costs directly attributable to such Sale and borne by Licensee, its Affiliates or its Sublicensee. Such qualifying costs shall be limited to the following: 

1.15.1 Discounts for quantity purchases, for prompt payments and for wholesalers and distributors; 

  
 -2-

 1.15.2 Credits or refunds, not exceeding the original invoice amount, for
claims or returns; 
 1.15.3 Prepaid outbound transportation expenses and transportation insurance premiums; and

 1.15.4 Sales and use taxes, tariff duties and other fees imposed by a governmental agency. 

1.16. “Institute Licensed Product(s)” means products in the Field of Use that are made, made for, used or sold by Licensee or
any Sublicensees and that in the absence of this Agreement, the manufacture, sale or use of which would infringe at least one claim of Institute Patent Rights, or require the use of Institute Technical Information or an Improvement. 

1.17. “Institute Patent Rights” means all patent rights represented by or issuing from the United States or foreign patents
listed in Attachment 1 or the patents issuing from the United States or foreign patent applications listed in Attachment 1, and their foreign counterparts and extensions, including continuation, divisional and re-issue applications 

1.18. “Institute Technical Information” means proprietary, unpatented information owned by the Institute at the time of filing a
patent application set forth as part of the Patent Rights that is necessary to practice in the Field of Use the inventions disclosed in such patent application and which information is described in Attachment 1. 

1.19. “Sale” means any bona fide transaction for which consideration is received for the sale of Institute Licensed Product(s).
A Sale of Institute Licensed Product(s) shall be deemed completed at the time Licensee or its Sublicensee recognizes revenues for the sale of such Institute Licensed Product(s). 

1.20. “Sell Off Right” shall have the meaning given in Section 5.7. 

1.21. [omitted] 

1.22. “Sublicense” shall have the meaning given in Section 2.4.1. 

1.23. “Sublicensee” shall have the meaning given in Section 2.4.3. 

1.24. “Sublicense Revenues” shall have the meaning given in Section 3.1.3. 

1.25. “Warrant” shall have the meaning given in Section 3.1.2. 

1.26. [omitted] 

  
 -3-

 1.27. “Trigger Event” means any of the following: 

 

	 	1.27.1	If Licensee becomes insolvent, bankrupt or generally fails to pay its debts as such debts become due; is adjudicated insolvent or bankrupt; admits in writing its
inability to pay its debts; or shall suffer a custodian, receiver or trustee for it or substantially all of its property to be appointed and, if appointed without its consent, not be discharged within thirty (30) days; makes an Assignment for
the benefit of creditors; or suffers proceedings under any law related to bankruptcy, insolvency, liquidation or the reorganization, readjustment or the release of debtors to be instituted against it and, if contested by it, not dismissed or stayed
within ten (10) days; 

 1.27.2 If proceedings under any law related to bankruptcy, insolvency, liquidation,
or the reorganization, readjustment or the release of debtors are instituted or commenced by Licensee; 
 1.27.3 If any order
for relief is entered relating to any of the proceedings described in Sections 1.27.1 or 1.27.2; 
 1.27.4 If Licensee shall
call a meeting of its creditors with a view to arranging a composition or adjustment of its debts; or 
 1.27.5 If Licensee
shall by any act or failure to act indicate its consent to, approval of or acquiescence in any of the proceedings described in Sections 1.27.1 through 1.27.4. 
 ARTICLE 2 
 LICENSE GRANT 

2.1. License Grant. Institute grants to Licensee and its Affiliates for the term of this Agreement a worldwide, royalty-bearing
license under the Institute Patent Rights and the Institute Technical Information to make, have made, use, import, sell and offer for sale or otherwise dispose of the Institute Licensed Product(s) in the Field of Use, except that to the extent that
any Affiliate exercises any rights granted by Institute hereunder, Licensee remains primarily liable to Institute for the duties and obligations of any Affiliate hereunder, and any act or omission of an Affiliate would be deemed to be a breach by
Licensee of this Agreement, provided, however that Licensee shall have no liability hereunder with respect to any act or omission of an assignee if such assignment is effected in accordance with Section 10.2. Institute grants to Licensee the
right to grant sublicenses subject only to the limitations set forth in Section 2.4. 
 Institute further agrees to grant to
Licensee and its Affiliates licenses of the scope specified in the paragraph above in respect to any Improvements (as defined in Section 1.9, above). 

  
 -4-

 2.2. Exclusivity. The License is exclusive for Institute Patent Rights, Institute
Technical Information (and for Improvements to the extent they are not embodied in issued patent claims) in the Field of Use, except that Institute may use the Institute Patent Rights, Improvements and Institute Technical Information for its own
non-commercial educational and research purposes. On or after the Effective Date, Institute shall have no right to grant a license to the Institute Patent Rights or Institute Technical Information in the Field of Use to any person or
entity. 
 2.3. U.S. Government Rights. Licensee or its Affiliates acknowledge that pursuant to Public Laws 96-517, 97-256
and 98-620, codified at 35 U.S.C. 200-212, the United States government retains certain rights in intellectual property funded in whole or part under any contract, grant or similar agreement with a Federal agency. Pursuant to these laws, the
government may impose certain requirements regarding such intellectual property, including, but not limited to the requirement that products resulting from such intellectual property sold in the United States must be substantially manufactured in
the United States. The License is expressly subject to all applicable United States government rights as provided in the above-mentioned laws and any regulations issued under those laws, as those laws or regulations may be amended from time to time.

 2.4. Sublicense Conditions. The right to sublicense granted to Licensee under Section 2.1 is subject to the
following conditions: 
 2.4.1 Licensee may sublicense the rights granted in this Agreement by written sublicense
agreement which agreement shall require that the sublicensee (“Sublicensee”) be subject to the terms and conditions of the license granted to Licensee under this Agreement (each, a “Sublicense”). Licensee may grant to a
Sublicensee the right to grant sublicenses. 
 2.4.2 Within [**] days after Licensee enters into any Sublicense,
Licensee shall deliver to Institute a complete copy of the Sublicense written in the English language (receipt of a Sublicense shall not constitute an approval of the Sublicense or a waiver of any of Institute’s rights or Licensee’s
obligations under this Agreement). 
 2.4.3 In the event of a Default under Section 5.3 hereunder, all
payments then or thereafter due to Licensee from each of its Sublicensees shall, upon notice from Institute to any such Sublicensee, become owed directly to Institute for the account of Licensee; provided that Institute shall remit to Licensee the
amount by which such payments in the aggregate exceed the total amount owed by Licensee to Institute. 
 2.4.4
Even if Licensee enters into Sublicenses, Licensee remains primarily liable to Institute for all of Licensee’s duties and obligations contained in this Agreement, and any act or omission of a Sublicensee that would be a breach of this Agreement
if performed by Licensee shall be deemed to be a breach by Licensee of this Agreement. 

  
 -5-

 ARTICLE 3 
 FEES, WARRANTS, RESEARCH GRANT, ROYALTIES 
 AND MILESTONE PAYMENTS

 3.1. Fees, Warrants and Royalties. 
 3.1.1 Initial Cash Payments. In partial consideration of the License, Licensee shall pay to Institute a non-refundable amount equal to documented attorneys fees, expenses, official fees and other
charges incident to the preparation, prosecution and maintenance of Institute Patent Rights incurred prior to the Effective Date by Institute, not to exceed [**] Dollars ($[**]). Licensee shall pay such amounts within [**] days after receipt of
documentation reasonably demonstrating such expenses. 
 3.1.2 [Omitted] 

3.1.3 Royalties. In further consideration of the exclusive license granted to Licensee, Licensee shall pay (or cause its Affiliates
to pay) to Institute a royalty of [**] percent ([**]%) of the Net Sales of Institute Licensed Products sold by Licensee or its Affiliates, provided, however, that if Licensee determines that it is required to license other technology to produce and
sell Institute Licensed Products, then the royalty rate hereunder shall be reduced by [**] percent ([**]%) of the royalty rate due with respect to the other technology, but in no event shall royalties payable to Institute under this
Section 3.1.3 be less than [**] percent ([**]%) of the Net Sales of Institute Licensed Products sold by Licensee and its Affiliates. 
 3.1.4 Sublicense Royalties. In further consideration of the exclusive license granted to Licensee, Licensee shall pay (or cause its Affiliates to pay) to Institute a royalty of [**] percent ([**]%)
of the Net Sales of Institute Licensed Products sold by Sublicensees, provided, however, that if Licensee or such Sublicensee determines that it is required to license other technology to produce and sell Institute Licensed Products, then the
royalty rate hereunder shall be reduced by [**] percent ([**]%) of the royalty rate due with respect to the other technology, but in no event shall royalties payable to Institute under this Section 3.1.4 be less than [**] percent ([**]%) of the
Net Sales of Institute Licensed Products sold by Sublicensees. 

  
 -6-

 3.1.5 Milestone Payments. In further consideration of the exclusive license granted
to Licensee, Licensee shall pay to Institute the following amounts: (a) a milestone payment of [**] Dollars ($[**]) or shares of capital stock of Licensee with a fair market value equal to [**] Dollars ($[**]) (with the form of payment
determined by the Licensee in its discretion), payable within [**] days following the filing by the Licensee, its Affiliate or Sublicensee of the first biologics license application, or similar application with the U.S. Food and Drug Administration
(the “FDA”) for a clinical application of a product that requires a license to Institute Patent Rights; and (b) a milestone payment of [**] Dollars ($[**]) or shares of capital stock of Licensee with a fair market value equal to [**]
Dollars ($[**]) (with the form of payment determined by Licensee in its discretion), payable within [**] days following the approval by the FDA of commercial sale of the first product that requires a license to Institute Patent Rights. For the
avoidance of doubt, the parties acknowledge that regardless of the number of inventions licensed by Licensee from Institute, Licensee shall have no obligation to make milestone payments as described in this Section 3.1.5 more than once for each
product. These milestone payments shall be in lieu of any payment to Institute of any portion of any up-front, milestone or similar payments to Licensee under any Sublicense. All shares of capital stock of Licensee issued to Institute hereunder
shall be registered and freely salable if the capital stock of Licensee is publicly traded on a recognized exchange or over-the-counter, and shall be subject to registration rights, on parity with the founders’ rights, if the stock of Licensee
is not then traded on an exchange or over-the-counter market(s). 
 3.1.6 Payments to Inventors. Institute shall be solely
responsible for making any payments due to inventors under any policy or contract applicable to Institute and shall hold Licensee harmless with respect to any such claims. 
 3.2. Diligence  
 3.2.1 Licensee shall use its best commercial efforts,
taking into account the size and capitalization of Licensee, to file (or cause an Affiliate or Sublicensee to file) a Biologics License Application or similar application with the FDA for a clinical application of a Institute Licensed Product within
[**] years from the Effective Date. 
 3.2.2 Licensee shall provide to Institute, on the first anniversary of the Effective Date
and on each anniversary thereafter, written progress reports, setting forth in such detail as Institute may reasonably request the progress of the development, evaluation, testing and commercialization of each Institute Licensed Product. Licensee
shall also notify Institute in writing within [**] days after the first commercial sale of each Institute Licensed Product. 

3.2.3 Licensee acknowledges the failure to use best commercial efforts to develop, evaluate, test and commercialize the Institute Licensed
Products shall be a material breach of this Agreement, provided, however, that Licensee receive prior written notice from Institute and be provided [**] days to cure such failure, and upon curing, there shall be no material breach. 

  
 -7-

 3.3. Royalty Reports and Records. 

3.3.1 Licensee shall deliver to Institute within [**] days after the end of each Calendar Half (or, with respect to Institute Licensed
Products sold by Sublicensees, within [**] days after the end of each Calendar Half) a written report, certified by the chief financial officer of Licensee, setting forth the calculation of the royalties due to Institute for such Calendar Half,
including, without limitation: 
 3.3.1.1 Number of Institute Licensed Products involved in Sales, listed by country; 

3.3.1.2 Gross consideration for Sales of Institute Licensed Products, including all amounts invoiced, billed, or received; 

3.3.1.3 Qualifying costs, as defined in Section 1.15, listed by category of cost; 

3.3.1.4 Net Sales of Institute Licensed Products listed by country; 

3.3.1.5 Royalties owed to Institute, listed by category, including without limitation earned and Sublicensee derived categories.

 3.3.2 Licensee shall pay the royalties due under Section 3.1.3 to Institute within [**] days following the last day of
the Calendar Half in which the royalties accrue. Licensee shall send Institute with such royalties the report described in Section 3.3.1. Licensee shall pay the royalties due under Section 3.1.4 to Institute within [**] days following the
last day of the Calendar Half in which the royalties accrue. Licensee shall send Institute with such royalties the report described in Section 3.3.1. 
 3.3.3 Licensee shall maintain and cause its Sublicensees to maintain, complete and accurate books and records that enable the royalties payable under this Agreement to be verified. The records for each
Calendar Half shall be maintained for [**] years after the submission of each report under Article 3. Upon reasonable prior notice to Licensee, Licensee shall provide Institute with access to all books and records relating to the Sales of Institute
Licensed Products by Licensee and its Sublicensees to conduct a review or audit of those books and records. Access to Licensee’s books and records shall be made available not more than [**] each calendar year, during normal business hours, and
during each of [**] years after the expiration or termination of this Agreement. If Licensee has underpaid any royalty due by five percent (5%) or more, then Licensee shall pay to Institute promptly the costs and expenses of Institute and its
accountants in connection with their review or audit, in addition to such underpayment. 

  
 -8-

 3.4. Currency, Place of Payment, Interest, Payment of Expenses. 

3.4.1 All dollar amounts referred to in this Agreement are expressed in United States dollars. All payments to Institute under this
Agreement shall be made in United States dollars by check payable to “Baylor Research Institute.” If Licensee receives any revenues in currency other than United States dollars, then such revenues shall be converted into United States
dollars at the conversion rate for the foreign currency as published in the eastern edition of The Wall Street Journal as of the last business day of the applicable Calendar Half. 

3.4.2 Amounts that are not paid when due shall accrue interest from the due date until paid, at a rate equal to [**] percent ([**]%) per
month or part thereof (or the maximum allowed by law, if less). 
 ARTICLE 4 

CONFIDENTIALITY 
 4.1. Non-Disclosure by Licensee. Licensee shall maintain in confidence and agrees not to disclose to any third party any Confidential Information of Institute. Licensee shall ensure that its
employees have access to Confidential Information only on a need-to-know basis and are obligated in writing to abide by Licensee’s obligations under this Agreement. The foregoing obligation shall not apply to: 

4.1.1 Information that is known to Licensee or independently developed by Licensee prior to the time of disclosure, in each case, to the
extent evidenced by written records promptly disclosed to Institute upon receipt of the Confidential Information; 
 4.1.2
Information disclosed to Licensee by a third party that has a right to make such disclosure; 
 4.1.3 Information that becomes
patented, published or otherwise part of the public domain as a result of acts by Institute or a third person obtaining such information as a matter of right; or 
 4.1.4 Information that is required to be disclosed by order of United States governmental authority or a court of competent jurisdiction; provided that Licensee shall use best efforts to obtain
confidential treatment of such information by the agency or court. 
 4.2. Limited Non-Disclosure by Institute. Institute
shall not be obligated to accept any confidential information from Licensee except for the reports required under this Agreement. Institute shall use the same level of care Institute uses to protect its own confidential information (and in any
event, not less than reasonable care) to prevent the disclosure of those reports to any third party other than Institute’s outside legal advisors (subject to exceptions substantially similar to these applicable to Licensee under Section 4.1)
who shall be obligated to treat such reports as confidential. Institute shall maintain in confidence and agrees not to disclose to any third party any confidential information received from Licensee. Institute shall ensure that its employees have
access to such confidential information only on a need-to-know basis and are obligated in writing to abide by Institute’s obligations under this Agreement. Institute bears no institutional responsibility for maintaining the confidentiality of
any other information of Licensee. 

  
 -9-

 ARTICLE 5 
 TERM AND TERMINATION 
 5.1. Term. This Agreement, unless sooner
terminated as provided in this Agreement, terminates upon the later of: (a) expiration of the last to expire or become abandoned of the Institute Patent Rights; or (b) twenty (20) years after the Effective Date. 

5.2. Termination by Licensee. Licensee may, upon sixty (60) days written notice to Institute, terminate this Agreement by
doing all of the following: 
 5.2.1 Ceasing to make, have made, use, import, sell and offer for sale all Institute Licensed
Products; and 
 5.2.2 Terminating all Sublicenses, and causing all Sublicensees and Affiliates to cease making, having made,
using, importing, selling and offering for sale all Institute Licensed Products; and 
 5.2.3 Paying all monies owed to Institute
under this Agreement and the Sponsored Research Agreement. 
 5.3. Termination by Institute. Institute may terminate this
Agreement if any of the following events of default (“Default”) occur: 
 5.3.1 Licensee is more than thirty
(30) days late in paying to Institute any monies due under this Agreement and Licensee does not pay Institute all uncontested amounts within ten (10) business days after Institute’s written demand; 

5.3.2 Licensee experiences a Trigger Event; 
 5.3.3 Licensee or any Affiliate or Sublicensee materially breaches this Agreement (other than a breach solely under Sections 5.3.1 or 5.3.2) and does not cure the breach within [**] days after written
notice of the breach or, if such breach is not curable within [**] days, such longer period as may be reasonably required to cure such breach. 

  
 -10-

 5.4. Effect of Termination. In the event of a termination under Sections 5.2 or 5.3
hereof, all duties of Institute and all rights (but not duties) of Licensee and any Affiliate and/or Sublicensee under this Agreement shall immediately terminate without the necessity of any action being taken either by Institute or by Licensee or
any Affiliate or Sublicensee. Upon and after any termination of this Agreement, Licensee and any Affiliate and/or Sublicensee shall refrain from further manufacture, sale, marketing, importation, and/or distribution of Institute Licensed Product(s),
except as provided in this Article 5. Licensee acknowledges that termination shall not affect Institute’s rights and privileges as a stockholder of Licensee nor its ownership of shares in Licensee. 

5.5. Return of Confidential Information. Upon termination of this Agreement, Licensee and any Affiliate and/or Sublicensee shall,
at Institute’s request, return to Institute all Confidential Information (provided that Licensee may retain one copy with the offices of its outside legal counsel), as well as copies of any data generated by Licensee and any Affiliate and/or
Sublicensee during the term of this Agreement that will facilitate the development of the technology licensed under this Agreement. 
 5.6. Inventories. Upon termination of this Agreement, Licensee shall cause physical inventories to be taken immediately of: (a) all completed Institute Licensed Product(s) on hand under the
control of Licensee or any Affiliate or Sublicensee; and (b) such Institute Licensed Product(s) as are in the process of manufacture and component parts thereof as of the date of termination of this Agreement, which inventories shall be reduced
to writing. Licensee shall deliver copies of such written inventories, verified by an officer of Licensee forthwith to Institute. Institute shall have [**] days after receipt of such verified inventories within which to challenge the inventory and
request an audit. Upon [**] days written notice to Licensee, Institute and its agents shall be given access during business hours to the premises of Licensee, its Affiliates and/or Sublicensees for the purpose of conducting an audit. Upon the
termination of this Agreement, Licensee shall, at its own expense forthwith remove, efface or destroy all references to Institute from all advertising or other materials used in the promotion of Licensee’s business or the business of any
Affiliate or Sublicensee and Licensee and any Affiliate and/or Sublicensee shall not thereafter represent in any manner that it has rights in or to the Institute Patent Rights or Institute Licensed Product(s). 

5.7. Sell Off Rights. Notwithstanding the foregoing, if this Agreement terminates other than pursuant to Section 5.3, Licensee
and its Affiliates and Sublicensees shall have the right to sell off its inventory of Institute Licensed Product(s) existing on the date of termination of this Agreement (“Sell Off Right”), subject to the royalty obligation of
Section 3.1.3 . 
 5.8. Survival. Licensee’s obligation to pay all monies owed accruing under this Agreement
shall survive termination of this Agreement. In addition, the provisions of Article 4 - Confidentiality, Article 5 - Term and Termination, Article 8 - Disclaimer of Warranties; Indemnification, Article 9 - Use of Institute’s Name; Independent
Contractor and Article 10 - Additional Provisions shall survive such termination. 

  
 -11-

 ARTICLE 6 
 PATENT MAINTENANCE 
 As of the Effective Date, Licensee
will assume the primary responsibility for applying for, seeking prompt issuance of, and maintaining the Institute Patent Rights during the term of this Agreement. Without limiting the generality of the foregoing, Licensee shall be entitled to use
patent counsel of its choice and Institute shall use all reasonable efforts to cause Institute’s patent counsel to deliver files to Licensee’s counsel and otherwise to cooperate with Licensee and Licensee’s patent counsel relating to
such prosecution. Licensee shall diligently and in a timely manner provide Institute with copies of filings relating to the prosecution, maintenance, and validity of the Institute Patent Rights. Licensee shall consult with Institute in such
prosecution and maintenance, and shall diligently seek strong and broad claims under the Institute Patent Rights and shall not abandon prosecution of any Institute Patent Rights without first notifying Institute in a timely manner of Licensee’s
intention and reason therefore, and providing Institute with reasonable opportunity to assume responsibility for prosecution and maintenance of the Institute Patent Rights. Licensee shall identify all claims (or potential for claims it is aware of)
which are wholly or partially outside of the Field of Use, and abide by all requests of Institute regarding prosecution of claims which are wholly or partly outside of the Field of Use. If the Institute believes, in good faith and after consultation
with Licensee, that Licensee is not fulfilling its duties under this Article, then Institute may resume responsibility for prosecution of the patents, and Licensee shall reimburse Institute for all costs expended by Licensee in prosecuting the
patents. 
 ARTICLE 7 
 INFRINGEMENT AND LITIGATION 
 7.1. Notification of Infringement.
Institute and Licensee are responsible for notifying each other promptly of any infringement of Institute Patent Rights, which may come to their attention. Institute and Licensee shall consult one another in a timely manner concerning any
appropriate response to the infringement. 
 7.2. Prosecution by Licensee. Licensee may prosecute such infringement at its
own expense. Licensee shall not settle or compromise any such suit in a manner that imposes any obligations or restrictions on Institute without Institute’s prior written permission, which permission shall not be unreasonably withheld (provided
however that no permission shall be required for Licensee to grant a non-royalty bearing Sublicense as part of such settlement if Licensee reasonably determines that such grant is necessary or appropriate to avoid litigation or similar controversy).
Financial recoveries from any such litigation will first be applied to reimburse Licensee for its litigation expenditures with additional recoveries being paid to Licensee, subject to a royalty due Institute based on the provisions of Article 3.

  
 -12-

 7.3. Prosecution by Institute. If Licensee fails to prosecute any infringement, then
Institute may prosecute such infringement at its own expense. In such event, financial recoveries will be entirely retained by Institute. 
 7.4. Cooperation. In any action to enforce any of the Institute Patent Rights, either party, at the request and expense of the other party shall cooperate to the fullest extent reasonably possible.
This provision shall not be construed to require either party to undertake any activities, including legal discovery, at the request of any third party except as may be required by lawful process of a court of competent jurisdiction. 

ARTICLE 8 

REPRESENTATIONS, DISCLAIMER OF WARRANTIES; INDEMNIFICATION 

8.1. Representations. 
 8.1.1 Institute represents and warrants to Licensee as follows: Institute is the exclusive owner of the Institute Patent Rights and the Institute Technical Information. Institute is not a party to or
bound by any license or other agreement that grants any person any rights with respect to the Institute Patent Rights; provided, however, Licensee acknowledges Institute’s written policy for sharing net proceeds on intellectual property with
the applicable inventors, for which Institute assumes all responsibility. The grant of the License under this Agreement does not conflict with any agreement to which Institute is a party. Institute has not received any written charge, complaint,
claim, demand, or notice alleging that the development and use of the Institute Patent Rights or the Institute Technical Information has interfered with, misappropriated any valid patent claims of third parties. No litigation is pending and no claim
has been made against Institute or, to the knowledge of Institute, is threatened, which contests the right of Institute to license to Licensee the Institute Patent Rights or the Institute Technical Information. The knowledge of Institute is limited
to the actual knowledge of Dr. [**] and persons employed in Institute’s office of technology transfer and office of the general counsel. 
 8.1.2 NO OTHER WARRANTIES. THE INSTITUTE PATENT RIGHTS, INSTITUTE TECHNICAL INFORMATION, INSTITUTE LICENSED PRODUCTS AND ALL OTHER TECHNOLOGY LICENSED UNDER THIS AGREEMENT ARE PROVIDED ON AN
“AS IS” BASIS, AND, INSTITUTE MAKES NO REPRESENTATIONS OR WARRANTIES, EXPRESS OR IMPLIED, WITH RESPECT THERETO EXCEPT AS SET FORTH IN SECTION 8.1.1. BY WAY OF EXAMPLE BUT NOT OF LIMITATION, INSTITUTE MAKES NO REPRESENTATIONS OR WARRANTIES:
(a) OF COMMERCIAL UTILITY; (b) OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE; OR (c) EXCEPT AS SET FORTH IN SECTION 8.1.1, THAT THE USE OF THE INSTITUTE PATENT RIGHTS, INSTITUTE TECHNICAL INFORMATION, INSTITUTE LICENSED
PRODUCTS OR ANY TECHNOLOGY LICENSED UNDER THIS AGREEMENT WILL NOT INFRINGE ANY PATENT, COPYRIGHT, TRADE SECRET OR TRADEMARK OR OTHER PROPRIETARY OR PROPERTY RIGHTS OF OTHERS. INSTITUTE SHALL NOT BE LIABLE TO LICENSEE, AFFILIATES, LICENSEE’S
SUBLICENSEES OR THEIR RESPECTIVE SUCCESSORS OR ASSIGNS OR ANY THIRD PARTY WITH RESPECT TO: ANY CLAIM ARISING FROM USE OF THE INSTITUTE PATENT RIGHTS, INSTITUTE TECHNICAL INFORMATION, INSTITUTE LICENSED PRODUCTS OR ANY TECHNOLOGY LICENSED UNDER THIS
AGREEMENT OR FROM THE MANUFACTURE, USE OR SALE OF INSTITUTE LICENSED PRODUCTS; OR ANY CLAIM FOR LOSS OF PROFITS, LOSS OR INTERRUPTION OF BUSINESS, OR FOR INDIRECT, SPECIAL OR CONSEQUENTIAL DAMAGES OF ANY KIND EXCEPT TO THE EXTENT THAT ANY SUCH CLAIM
IS ATTRIBUTABLE TO A BREACH BY INSTITUTE OF SECTION 8.1.1. 

  
 -13-

 8.2. Indemnification. Licensee shall indemnify, defend and hold harmless Institute,
its trustees, officers, agents and employees (individually, an “Indemnified Party”, and collectively, the “Indemnified Parties”), from and against any and all liability, loss, damage, action, claim or expense suffered or incurred
by the Indemnified Parties (including attorneys’ fees and expenses) (individually, a “Liability”, and collectively, the “Liabilities”) that results from or arises out of: (a) the development, use, manufacture,
promotion, sale or other disposition of any Institute Technical Information, Institute Patent Rights, or Institute Licensed Products by Licensee, its Affiliates, its assignees, Sublicensees, vendors or other third parties; (b) any breach by
Licensee or its Affiliates or Sublicensees of this Agreement; and (c) the enforcement by an Indemnified Party of this Section 8.2. Without limiting the foregoing, Licensee shall defend, indemnify, and hold harmless the Indemnified Parties
from and against any Liabilities resulting from: 
 8.2.1 Any product liability or other claim of any kind related to the use by
a third party of a Institute Licensed Product that was manufactured, sold or otherwise disposed by Licensee, its Affiliates, its assignees, Sublicensees or vendors; 
 8.3.2 A claim by a third party that the Institute Technical Information or Institute Patent Rights or the design, composition, manufacture, use, sale or other disposition of any Institute Licensed Product
infringes or violates any patent, copyright, trade secret, trademark or other intellectual property rights of such third party, except to the extent such claim is attributable to a breach of Section 8.1.1; and 

8.2.3 Clinical trials or studies conducted by or on behalf of Licensee, its Affiliates, its assignees, Sublicensees or agents relating to
the Institute Technical Information, Institute Patent Rights or Institute Licensed Products, including, without limitation, any claim by or on behalf of a human subject of any such clinical trial or study, any claim arising from the procedures
specified in any protocol used in any such clinical trial or study, any claim of deviation, authorized or unauthorized, from the protocols of any such clinical trial or study, and any claim resulting from or arising out of the manufacture or quality
control by a third party of any substance administered in any clinical trial or study provided, that Licensee shall have no obligation to indemnify any Indemnified Party to the extent that any loss or damage is attributable to the negligence or
misconduct of such Indemnified Party or its employees or representatives. 

  
 -14-

 8.3. Rights of Institute in Liability Action. Licensee is not permitted to settle or
compromise any claim or action giving rise to Liabilities in a manner that imposes any restrictions or obligations on Institute without Institute’s prior written consent, which consent shall not be unreasonably withheld. If Licensee fails or
declines to assume the defense of any such claim or action within [**] days after notice thereof, then Institute may assume the defense of such claim or action for the account and at the risk of Licensee, and any Liabilities related thereto shall be
conclusively deemed a liability of Licensee. The indemnification rights of Institute or other Indemnified Party contained herein are in addition to all other rights that such Indemnified Party may have at law or in equity or otherwise. 

8.4. Insurance. 
 8.4.1 Licensee and any Affiliate shall procure and maintain a policy or policies of comprehensive general liability insurance, including broad form and contractual liability, in a minimum amount of $[**]
combined single limit per occurrence and in the aggregate as respects personal injury, bodily injury and property damage arising out of such party’s performance of this Agreement. 

8.4.2 Licensee and any Affiliate shall, upon commencement of clinical trials involving Institute Licensed Products, procure and maintain a
policy or policies of product liability insurance in a minimum amount of $[**] combined single limit per occurrence and in the aggregate as respects bodily injury and property damage arising out of such party’s performance of this Agreement.

 8.4.3 The policy or policies of insurance described in this Section 8.4 shall be issued by an insurance carrier with an
A.M. Best rating of “A” or better and shall name Institute as an additional insured with respect to Licensee’s performance of this Agreement. Licensee and any Affiliate shall, upon reasonable request, provide Institute with
certificates evidencing the insurance coverage required herein and all subsequent renewals thereof. Such certificates shall provide that the insurance carrier(s) notify Institute in writing at least [**] days prior to cancellation or material change
in coverage. 
 8.4.4 Institute may periodically review the adequacy of the minimum limits of liability insurance specified in
this Section, and Institute reserves the right to request Licensee and any Affiliate to adjust the liability insurance coverages. Licensee will consider any reasonable request to adjust the liability insurance coverages. The specified minimum
insurance amounts do not constitute a limitation on the obligation of Licensee and any Affiliate to indemnify Institute under this Agreement. 

  
 -15-

 ARTICLE 9 
 USE OF INSTITUTE’S NAME 
 Licensee and its Affiliates, employees,
Sublicensees and agents shall not use, and Licensee shall not permit its Sublicensees to use, Institute’s name or any adaptation thereof, or any Institute seal, logotype, trademark, or service mark, or the name, mark, or logotype of any
Institute representative or organization in any way without the prior written consent of Institute in it sole discretion. Institute hereby consents to the disclosure of the existence and terms of this Agreement by Licensee in the ordinary course of
Licensee’s business, including without limitation the disclosure hereof to current and prospective Sublicensees, investors, research collaborators, and strategic partners. 
 Licensee acknowledges Institute, Baylor Health Care System, and Baylor University Medical Center are not affiliated with Baylor University or Baylor College of Medicine, and Licensee will make no
reference to the University or College of Medicine in any publications without the prior written consent of such separate organization. 
 ARTICLE 10 
 ADDITIONAL PROVISIONS 

10.1. No Agency. Nothing in this Agreement shall be deemed to establish a relationship of principal and agent between Institute
and Licensee or its Affiliates or Sublicensees, nor any of their agents or employees for any purpose whatsoever, nor shall this Agreement be construed as creating any other form of legal association or arrangement which would impose liability upon
one party for the act or failure to act of the other party. 
 10.2. Assignment. Licensee together with its Affiliates and
Sublicensees are not permitted to assign this Agreement or any part of it, either directly or by merger or other operation of law, without the prior written consent of Institute, which consent shall not be unreasonably withheld, provided that no
such consent shall be required if (a) this Agreement is assigned in connection with the sale of all or substantially all of the assets or stock of Licensee, whether by merger, acquisition or otherwise or (b) this Agreement is assigned to
an Affiliate of Licensee or transferred to a partnership, limited liability company, joint venture or similar enterprise in which Licensee has rights to receive at least [**]% of the profits. Any prohibited assignment of this Agreement or the rights
hereunder shall be null and void. No assignment effected without Institute’s consent relieves Licensee, its Affiliates, and/or Sublicensees of responsibility for the performance of any accrued obligations that Licensee, its Affiliates and/or
Sublicensees has prior to such assignment. 

  
 -16-

 10.3. No Waiver. No waiver of any breach or condition of this Agreement shall be
deemed to be a waiver of any other subsequent breach or condition, whether of like or different nature. 
 10.4. Notices.
All notices, requests, consents and other communications hereunder shall be in writing and shall be delivered in person or sent overnight delivery by Federal Express or by certified or registered mail, return receipt requested, or telexed in the
case of non-U.S. residents, and shall be deemed to have been given when hand delivered, one (1) day after mailing when mailed by overnight courier (e.g. Federal Express or Express Mail) or five (5) days after mailing by registered or
certified mail, as follows (provided that notice of change of address shall be deemed given only when received): 
 If to
Institute: 
 Baylor Research Institute 
 3434 Live Oak 
 Dallas, Texas, 75204. 

Attention: President 
 With a required copy to: 
 Baylor Research Institute 

3434 Live Oak 

Dallas, Texas, 75204. 
 Attention: General Counsel 
 If to Licensee: 

MERIX Bioscience, Inc. 
 4233 Technology Drive 
 Durham, North Carolina 27704 

Attention: Chief Executive Officer 
 With a required copy to: 
 Hutchison & Mason PLLC 

3110 Edwards Mill Road, Suite 100 
 Raleigh, North Carolina 27612 
 Attention: Fred D. Hutchison, Esq. 

  
 -17-

 or to such other names or addresses as Licensee or Institute, as the case may be, shall
designate by notice to each other person entitled to receive notices in the manner specified in this Section 10.4. 
 10.5.
Governing Law and Arbitration. This Agreement shall be construed and governed in accordance with the laws of the State of North Carolina, without giving effect to conflict of law provisions of any jurisdiction. In the event that a party to
this Agreement perceives the existence of a dispute with the other party concerning any right or duty provided for herein, the parties will, as soon as practicable, confer in an attempt to resolve the dispute. Except as to issues relating to the
validity, enforceability or final determination of infringement of any patent contained in the Institute Patent Rights licensed hereunder, any and all claims, disputes or controversies arising under, out of, or in connection with this Agreement,
which have not been resolved in good faith negotiations between the parties, shall be resolved by a board of three (3) arbitrators in accordance with the rules, then in effect, of the American Arbitration Association. If the Arbitration is
brought by Institute, it shall take place in Durham, North Carolina, and if brought by Licensee, it shall take place in Dallas, Texas. Such independent board shall be composed of three (3) panelists of sufficient education, scientific
experience, and national reputation to address such issues. The board shall be composed of one arbitrator selected by Institute, one selected by Licensee and one selected by Licensee and Institute. If Licensee and Institute cannot agree upon the
third arbitrator within [**] days after the notice of arbitration, the third arbitrator shall be selected by the American Arbitration Association in accordance with its rules. The decision of such panel shall be final and binding upon the parties
and enforceable in any court of competent jurisdiction. 
 10.6. No Discrimination. Institute and Licensee and its
Affiliates shall not discriminate against any employee or applicant for employment because of race, color, sex, sexual or affectional preference, age, religion, national or ethnic origin, handicap, or because he or she is a disabled veteran or a
veteran of the Vietnam Era and Licensee shall include in each Sublicense a commitment by each Sublicensee to comply with all applicable employment discrimination laws. 
 10.7. Compliance with Laws. Institute, Licensee, its Affiliates and Sublicensees shall comply with all prevailing laws, rules and regulations that apply to its activities or obligations under this
Agreement, including, but not limited to, all applicable laws and regulations regarding “conflicts of interest” and institutional review imposed by the FDA, the U.S. Office of Human Research Protections, and otherwise. Without limiting the
foregoing, it is understood that this Agreement may be subject to United States laws and regulations controlling the export of technical data, computer software, laboratory prototypes and other commodities, articles and information, including the
Arms Export Control Act as amended in the Export Administration Act of 1979, and that the parties’ obligations are contingent upon compliance with applicable United States export laws and regulations. The transfer of certain technical data and
commodities may require a license from the cognizant agency of the United States Government and/or written assurances by Licensee, its Affiliates and/or Sublicensees that Licensee shall not export data or commodities to certain foreign countries
without prior approval of such agency. Institute neither represents that a license is not required nor that, if required, it will issue. 

  
 -18-

 10.8. Binding Nature of Agreement. This Agreement shall be binding upon and inure to
the benefit of the parties hereto and their respective heirs, personal representatives, successors and assigns, except that any assignment by Licensee must comply with Section 10.2 to be effective. 

10.9. Counterparts, Headings and Exhibits. This Agreement may be executed in two or more counterparts, each of which shall be
deemed an original, but all of which together shall constitute one and the same instrument. The headings used in this Agreement are for convenience only and are not to be considered in construing or interpreting any term or provision of this
Agreement. All Schedules and Exhibits hereto are hereby incorporated in this Agreement and made a part hereof. 
 10.10.
Integration and Amendment. This Agreement, the Warrant, the Stockholders Agreement, and the Sponsored Research Agreement embody the entire agreement and understanding among the parties hereto related to its subject matter and supersede all
prior agreements and understandings relating to the subject matter hereof or thereof. This Agreement may not be changed, modified, extended, or terminated except by written amendment executed by an authorized representative of Institute and
Licensee. 
 10.11. Severability. If any provision of this Agreement shall be held to be illegal, invalid or
unenforceable, then such illegality, invalidity or unenforceability shall attach only to such provision and shall not in any manner affect or render illegal, invalid or unenforceable any other provision of this Agreement, and this Agreement shall be
carried out as if any such illegal, invalid or unenforceable provision were not contained herein. 
 10.12. Number of
Days. In computing the number of days for purposes of this Agreement, all days shall be counted, including Saturdays, Sundays and holidays; provided that if the final day of any time period falls on a Saturday, Sunday or holiday on which Federal
banks are or may elect to be closed, then the final day shall be deemed to be the next day which is not a Saturday, Sunday or such holiday. 
 [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] 

  
 -19-

 IN WITNESS WHEREOF, the undersigned, intending to be legally bound, have caused this
Agreement to be executed by their duly authorized representatives. 
  

									
	BAYLOR RESEARCH INSTITUTE	 		 	MERIX BIOSCIENCE, INC.
					
	By:	 	 /s/ Michael Ramsay
	 		 	By:	 	 /s/ Stephen Elliston

					
	Name:	 	Michael Ramsay, M.D.	 		 	Name:	 	Stephen Elliston
					
	Title:	 	President	 		 	Title:	 	VP Business Development

  
 -20-

 LIST OF ATTACHMENTS 

Attachment 1 - Patent Application 
 [**] 

  
 -21-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00192-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00192-of-00352.parquet"}]]